{"title":"SeraCare","description":null,"products":[{"product_id":"seracare-seraseq-ffpe-wt-dna-rna-reference-material-0710-0137","title":"Seraseq® FFPE WT (DNA\/RNA) Reference Material","description":"\u003cp\u003eMolecular assays that profile tumor mutations in solid tissue biopsies require an efficient and precise evaluation of the pre-analytic portion of their workflow prior to downstream analysis by NGS or other methods. Contrived reference material or cell line-based standard can provide a critical input in the optimization of nucleic acid extraction from very challenging FFPE tissue materials without wasting precious mutation-positive tissue samples.\u003c\/p\u003e\u003cp\u003eWe have designed this FFPE cell line-based reference sample as a negative control to support the determination of assay specificity at wildtype base positions, as well as specificity at positions affected by mutations included in all of the Seraseq RNA and DNA (Mutation Mix and Reference Material) products.\u003c\/p\u003e\u003cp\u003e\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eCell line-based negative control (WT)\u003c\/li\u003e\n\u003cli\u003eOffered as FFPE for full process assay (NGS or PCR) workflow optimization\u003c\/li\u003e \u003cli\u003eWell-characterized GM24385 wild-type material\u003c\/li\u003e\n\u003cli\u003eManufactured in GMP-compliant and ISO 13485-certified facilities\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eSpecifications\u003c\/h2\u003e\u003ctable\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e# of Variants\u003c\/td\u003e\n\u003ctd\u003e0\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAllele Frequency\u003c\/td\u003e\n\u003ctd\u003e0%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSize\u003c\/td\u003e\n\u003ctd\u003e10 µm\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFormat\u003c\/td\u003e\n\u003ctd\u003eFFPE\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDNA Yield\u003c\/td\u003e\n\u003ctd\u003e\u0026gt; 100 ng\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRNA Yield\u003c\/td\u003e\n\u003ctd\u003e\u0026gt; 300 ng\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e\u003ch2\u003eDocuments\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/ps-mkt-00525_seraseq-total-nucleic-acid-reference-materials.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq Total Nucleic Acid (Product Sheet)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/onc-060-mkt-00525-ps-seraseq-tna-reference-materials.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq Total Nucleic Acid Reference Materials (Product Sheet)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/pi-0710-0137-seraseq-ffpe-wt-dna-rna-reference-material.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq FFPE WT (DNA\/RNA) Reference Material (Package Insert)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/sds-seraseq-ffpe.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq FFPE Safety Data Sheet (Safety Data Sheet)\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eOrdering Information\u003c\/h2\u003e\u003ctable\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eCat. no.\u003c\/th\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eSize\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\u003ctr\u003e\n\u003ctd\u003e0710-0137\u003c\/td\u003e\n\u003ctd\u003eSeraseq® FFPE WT (DNA\/RNA) Reference Material\u003c\/td\u003e\n\u003ctd\u003e1 x 10 µm\u003c\/td\u003e\n\u003c\/tr\u003e\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"SeraCare","offers":[{"title":"Default Title","offer_id":46798509867087,"sku":"0710-0137","price":0.0,"currency_code":"ILS","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0712\/0748\/5519\/files\/0710-0137.jpg?v=1789655802"},{"product_id":"seracare-seraseq-tumor-mutation-dna-mix-v2-hc-0710-0094","title":"Seraseq® Tumor Mutation DNA Mix v2 HC","description":"\u003cp\u003eThe Seraseq Tumor Mutation DNA Mix v2 (AF10) HC is a multiplexed mixture of actionable biosynthetic DNA targets precisely blended with a single, well-characterized genomic background. This product is produced under rigorous design control and manufacturing practices to an allelic frequency of 10%, and is offered in a high concentration (HC) format at 25 ng\/µL. Designed to assess the overall performance of your somatic mutation assay by next-generation sequencing (NGS), this unique product includes a wide range of single nucleotide variants (SNVs), insertion-deletion mutations (indels), and structural variants (SVs).\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eSingle-vial format for daily run use\u003c\/li\u003e\n\u003cli\u003e40 unique multiplexed variants across 28 genes (see table in Specifications tab)\u003c\/li\u003e\n\u003cul\u003e\n\u003cli\u003e20 SNVs\u003c\/li\u003e\n\u003cli\u003e5 SNVs that are part of homopolymers\u003c\/li\u003e\n\u003cli\u003e13 indels\u003c\/li\u003e\n\u003cli\u003e2 SVs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cli\u003eMutation targets quantitated with digital PCR\u003c\/li\u003e\n\u003cli\u003eWell-characterized GM24385 human genomic DNA as background wild-type material\u003c\/li\u003e\n\u003cli\u003eManufactured within cGMP-compliant, ISO 13485-certified facilities\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp\u003eThe Seraseq Tumor Mutation Mix-II DNA Mix v2 (AF10) HC is formulated for use with targeted next-generation sequencing (NGS) assays that detect mutations in key oncogenes and tumor suppressor genes. The Seraseq Tumor Mutation Mix-II DNA Mix v2 (AF10) HC is intended as a quality reference material for translational and disease research testing to monitor library preparation, sequencing, and variant allele detection under a given set of bioinformatics pipeline parameters.\u003c\/p\u003e\u003cp\u003eFor research use only. Not for use in diagnostic procedures.\u003c\/p\u003e\u003ch2\u003eDocuments\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/ps-mkt-00314-0710-0094-0710-0095-seraseq-tumor-mutation-dna-mix-v2-hc.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq Tumor Mutation DNA Mix v2 HC (Product Sheet)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/ps-mkt-00304-05_seraseq_tri-level_tumor_mutation_dna_mix_v2_hc.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq Tri-Level Tumor Mutation DNA Mix v2 HC (Product Sheet)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/pi-0710-0094-seraseq-tumor-mutation-dna-mix-v2-af10.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq Tumor Mutation DNA Mix v2 AF10 (Package Insert)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/pi-0710-0095-seraseq-tumor-mutation-dna-mix-v2-af7.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq Tumor Mutation DNA Mix v2 AF7 (Package Insert)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/pi-0710-0097-seraseq-tri-level-tumor-mutation-dna-mix-v2.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq Tri-Level Tumor Mutation DNA Mix v2 (Package Insert)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/tss-0710-0094-seraseq-tumor-mutation-dna-mix-v2.xlsx\" target=\"_blank\" rel=\"noopener\"\u003eTechnical Spreadsheet for Seraseq Tumor DNA Mutation DNA Mixes v2 HC (Technical Spreadsheet)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/nrl-0710-0094-0097-seraseq-tumor-mutation-dna.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq® Tumor Mutation Non-Requirement Letter (SDS Non-Requirement Letter)\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eOrdering Information\u003c\/h2\u003e\u003ctable\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eCat. no.\u003c\/th\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eSize\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e0710-0094\u003c\/td\u003e\n\u003ctd\u003eSeraseq® Tumor Mutation DNA Mix v2 AF 10 HC\u003c\/td\u003e\n\u003ctd\u003e1 x 25 µL\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e0710-0095\u003c\/td\u003e\n\u003ctd\u003eSeraseq® Tumor Mutation DNA Mix v2 AF 7 HC\u003c\/td\u003e\n\u003ctd\u003e1 x 25 µL\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e0710-0097\u003c\/td\u003e\n\u003ctd\u003eSeraseq® Tri-Level Tumor Mutation DNA Mix v2 HC\u003c\/td\u003e\n\u003ctd\u003e1 x 25 µL\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"SeraCare","offers":[{"title":"AF10%","offer_id":46798509768783,"sku":"0710-0094","price":0.0,"currency_code":"ILS","in_stock":true},{"title":"AF7%","offer_id":46798509801551,"sku":"0710-0095","price":0.0,"currency_code":"ILS","in_stock":true},{"title":"Tri-Level","offer_id":46798509834319,"sku":"0710-0097","price":0.0,"currency_code":"ILS","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0712\/0748\/5519\/files\/0710-0094.jpg?v=1789655802"},{"product_id":"seracare-seraseq-myeloid-mutation-dna-mix-0710-0408","title":"Seraseq® Myeloid Mutation DNA Mix","description":"\u003cp\u003eMolecular analysis of myeloid cancers, such as acute myeloid leukemia (AML) and chronic myeloid leukemia (CML), is rapidly shifting from single-site methods such as FISH and qPCR to highly-multiplexed next-generation sequencing (NGS) assays. Hence, there is an increasing demand for highly multiplexed, patient-like NGS reference materials covering a broad range of clinically relevant variants in order to ensure that new and existing myeloid assays are robust, accurate, and consistent. SeraCare has developed the industry's first comprehensive set of myeloid cancer reference materials in response to this critical market need.\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eSingle sample with 23 clinically-relevant DNA mutations across 16 genes (save $1000s in running costs)\u003c\/li\u003e\n\u003cli\u003eExpert-designed to ensure coverage across important variants (mix of SNVs, indels, and ITD) at relevant allele frequencies\u003c\/li\u003e\n\u003cli\u003eBuilt with innovative technology to produce patient-like sample characteristics and NGS assay performance\u003c\/li\u003e\n\u003cli\u003eMutation targets precisely quantitated with digital PCR\u003c\/li\u003e\n\u003cli\u003eSingle well-characterized GM24385 cell line as background wild-type material\u003c\/li\u003e\n\u003cli\u003eManufactured in GMP-compliant and ISO 13485-certified facilities\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eSpecifications\u003c\/h2\u003e\u003ctable\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e# of Variants\u003c\/td\u003e\n\u003ctd\u003e23\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAllele Frequency\u003c\/td\u003e\n\u003ctd\u003eVariants at either 5%, 10%, or 15%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eConcentrations\u003c\/td\u003e\n\u003ctd\u003e15 ng\/µL\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAmount\u003c\/td\u003e\n\u003ctd\u003e375 ng (single vial)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBuffer\u003c\/td\u003e\n\u003ctd\u003e1 mM Tris \/ 0.1 mM EDTA pH 8.0\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e\u003ch2\u003eDocuments\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/ps-0710-2646.2647.2648.2649.0407.0408-seraseq-myeloid-rm.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq Myeloid Reference Materials: DNA, RNA Fusion, ctDNA Product Sheet (Product Sheet)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/pi-0710-0408-seraseq-myeloid-mutation-dna-mix.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq Myeloid Mutation Package Insert DNA Mix (Package Insert)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/tss-0710-0408-seraseq-myeloid-mutation-dna-mix.xlsx\" target=\"_blank\" rel=\"noopener\"\u003eTechnical Spreadsheet for Seraseq Myeloid Mutation DNA Mix (Technical Spreadsheet)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/nrl-0710-0407-0416-seraseq-mix.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq Mix Safety Data Sheet (Non-Requirement Letter) (SDS Non-Requirement Letter)\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eOrdering Information\u003c\/h2\u003e\u003ctable\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eCat. no.\u003c\/th\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eSize\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\u003ctr\u003e\n\u003ctd\u003e0710-0408\u003c\/td\u003e\n\u003ctd\u003eSeraseq® Myeloid Mutation DNA Mix\u003c\/td\u003e\n\u003ctd\u003e1 x 25 µL\u003c\/td\u003e\n\u003c\/tr\u003e\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"SeraCare","offers":[{"title":"Default Title","offer_id":46798509965391,"sku":"0710-0408","price":0.0,"currency_code":"ILS","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0712\/0748\/5519\/files\/0710-0408.jpg?v=1789655807"},{"product_id":"seracare-seraseq-myeloid-fusion-rna-mix-0710-0407","title":"Seraseq® Myeloid Fusion RNA Mix","description":"\u003cp\u003eMolecular analysis of myeloid cancers, such as acute myeloid leukemia (AML) and chronic myeloid leukemia (CML), is rapidly shifting from single-site methods such as FISH and qPCR to highly-multiplexed next-generation sequencing (NGS) assays. Hence, there is an increasing demand for highly multiplexed, patient-like NGS reference materials covering a broad range of clinically relevant variants in order to ensure that new and existing myeloid assays are robust, accurate, and consistent. SeraCare has developed the industry's first comprehensive set of myeloid cancer reference materials in response to this critical market need.\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eSingle sample with 9 clinically-relevant RNA fusions (save $1000s in running costs)\u003c\/li\u003e\n\u003cli\u003eExpert-designed to ensure coverage across important prognostic markers (such as BCR-ABL)\u003c\/li\u003e\n\u003cli\u003eBuilt with innovative technology to produce patient-like sample characteristics and NGS assay performance\u003c\/li\u003e\n\u003cli\u003eMutation targets precisely quantitated with digital PCR\u003c\/li\u003e\n\u003cli\u003eSingle well-characterized GM24385 cell line as background wild-type material\u003c\/li\u003e\n\u003cli\u003eManufactured in GMP-compliant and ISO 13485-certified facilities\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eSpecifications\u003c\/h2\u003e\u003ctable\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e# of Fusions\u003c\/td\u003e\n\u003ctd\u003e9\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eConcentration\u003c\/td\u003e\n\u003ctd\u003e15 ng\/µL\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAmount\u003c\/td\u003e\n\u003ctd\u003e375 ng (single vial)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBuffer\u003c\/td\u003e\n\u003ctd\u003e1 mM Tris, pH 8.0\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e\u003ch2\u003eDocuments\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/ps-0710-2646.2647.2648.2649.0407.0408-seraseq-myeloid-rm.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq Myeloid Reference Materials: DNA, RNA Fusion, ctDNA Product Sheet (Product Sheet)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/pi-0710-0407-seraseq-myeloid-fusion-rna.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq Myeloid Fusion RNA Mix Package Insert (Package Insert)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/pi-0710-0407-Seraseq-myeloid-fusion-rna-mix.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq Myeloid Fusion RNA Mix (Package Insert)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/tss-0710-0407-seraseq-myeloid-fusion-rna-mix.xlsx\" target=\"_blank\" rel=\"noopener\"\u003eTechnical Spreadsheet for Seraseq Myeloid Fusion RNA Mix (Technical Spreadsheet)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/nrl-0710-0407-0416-seraseq-mix.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq Mix Safety Data Sheet (Non-Requirement Letter) (SDS Non-Requirement Letter)\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eOrdering Information\u003c\/h2\u003e\u003ctable\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eCat. no.\u003c\/th\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eSize\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\u003ctr\u003e\n\u003ctd\u003e0710-0407\u003c\/td\u003e\n\u003ctd\u003eSeraseq® Myeloid Fusion RNA Mix\u003c\/td\u003e\n\u003ctd\u003e1 x 25 µL\u003c\/td\u003e\n\u003c\/tr\u003e\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"SeraCare","offers":[{"title":"Default Title","offer_id":46798509998159,"sku":"0710-0407","price":0.0,"currency_code":"ILS","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0712\/0748\/5519\/files\/0710-0407.jpg?v=1789655809"},{"product_id":"seracare-seraseq-ffpe-tumor-fusion-rna-v4-reference-material-0710-0496","title":"Seraseq® FFPE Tumor Fusion RNA v4 Reference Material","description":"\u003cp\u003eAs the diagnostic testing paradigm for chromosomal translocations and other complex structural variants continues to shift from single-site Fluorescent In Situ Hybridization (FISH) and targeted RT-PCR to highly multiplexed next-generation sequencing (NGS) assays, there is increasing need for highly multiplexed reference materials for these difficult mutations.\u003c\/p\u003e\u003cp\u003eThe Seraseq FFPE Tumor Fusion RNA Reference Material v4 contains 18 clinically significant RNA fusions which are prevalent across different types of solid tumors, in an efficient single-sample format. RNA transcripts carrying structural variants are engineered into well-characterized wild-type cells. Cells are formalin-fixed and embedded in paraffin, and the FFPE block is cut into 10-micron sections, each of which typically yields \u0026gt;400 ng of purified total RNA. The transcript level for each fusion is quantified using highly sensitive digital PCR to establish ground-truth (and orthogonally validated with NGS), which helps ensure the material remains constant over time.\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003e18 clinically relevant fusions evaluate assay sensitivity and specificity for important diagnostic, prognostic, and therapeutic targets\u003c\/li\u003e\n\u003cli\u003eFull-process FFPE format may be treated like a clinical specimen, which can reveal pre-analytic variability\u003c\/li\u003e\n\u003cli\u003e Quantification of transcript levels by dPCR establishes ground-truth and simplifies dilutions for Limit of Detection (LoD) experiments\u003c\/li\u003e\n\u003cli\u003eWell-characterized GM24385 human genomic DNA as background wild-type material\u003c\/li\u003e\n\u003cli\u003e Manufactured in GMP-compliant and ISO 13485-certified facilities\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp\u003eFor research use only. Not for use in diagnostic procedures.\u003c\/p\u003e\u003ch2\u003eSpecifications\u003c\/h2\u003e\u003ctable\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e# of Fusions\u003c\/td\u003e\n\u003ctd\u003e18\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSize\u003c\/td\u003e\n\u003ctd\u003e10 µm\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFormat\u003c\/td\u003e\n\u003ctd\u003eFFPE\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRNA Yield\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;400 ng\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e\u003ch2\u003eDocuments\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/ps-mkt-00443-02-seracare_seraseq_fusion_rna_ref_mat_.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq Fusion RNA Reference Materials (Product Sheet)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/pi-0710-0496-seraseq-ffpe-fusion-rna-v4-reference-material.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq FFPE Fusion RNA v4 Reference Material (Package Insert)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/tss-0710-0496.0497-seraseq-ffpe-tumor-fusion-rna-v4.xlsx\" target=\"_blank\" rel=\"noopener\"\u003eTechnical Spreadsheet for Seraseq Tumor Fusion RNA v4 Reference Materials (Technical Spreadsheet)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/sds-seraseq-ffpe.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq FFPE Safety Data Sheet (Safety Data Sheet)\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eOrdering Information\u003c\/h2\u003e\u003ctable\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eCat. no.\u003c\/th\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eSize\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\u003ctr\u003e\n\u003ctd\u003e0710-0496\u003c\/td\u003e\n\u003ctd\u003eSeraseq® FFPE Tumor Fusion RNA v4 Reference Material\u003c\/td\u003e\n\u003ctd\u003e1 x 10 µm\u003c\/td\u003e\n\u003c\/tr\u003e\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"SeraCare","offers":[{"title":"Default Title","offer_id":46798510096463,"sku":"0710-0496","price":0.0,"currency_code":"ILS","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0712\/0748\/5519\/files\/0710-0496.jpg?v=1789655814"},{"product_id":"seracare-seraseq-fusion-rna-mix-v4-0710-0497","title":"Seraseq® Fusion RNA Mix v4","description":"\u003cp\u003eAs diagnostic testing for chromosomal translocations and other complex structural variants continues to shift from single-site methods such as Fluorescent In Situ Hybridization (FISH) and targeted reverse transcription PCR (RT-PCR) to highly multiplexed next-generation sequencing (NGS) assays, there is an increasing need for highly multiplexed reference materials covering such mutations which may be rare or difficult to obtain. SeraCare continues to innovate to address this critical market need with an updated version designed for use with NGS assays that detect gene fusions via sequencing of RNA transcripts.\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eSingle sample with 18 clinically-relevant RNA gene fusions\u003c\/li\u003e\n\u003cli\u003ePurified RNA format is easy to use and eliminates extraction variability\u003c\/li\u003e\n\u003cli\u003eQuantification of transcript levels by dPCR establishes ground-truth and simplifies dilutions for limit of detection (LOD) experiments\u003c\/li\u003e\n\u003cli\u003eTotal RNA from well-characterized GM24385 cell line as background wild-type material\u003c\/li\u003e\n\u003cli\u003eManufactured in GMP-compliant and ISO 13485-certified facilities\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp\u003eFor research use only. Not for use in diagnostic procedures.\u003c\/p\u003e\u003ch2\u003eSpecifications\u003c\/h2\u003e\u003ctable\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e# of Fusions\u003c\/td\u003e\n\u003ctd\u003e18\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eConcentration\u003c\/td\u003e\n\u003ctd\u003e25 ng\/µL\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAmount\u003c\/td\u003e\n\u003ctd\u003e625 ng\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFormat\u003c\/td\u003e\n\u003ctd\u003ePurified RNA\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBuffer\u003c\/td\u003e\n\u003ctd\u003e1 mM Tris, pH 8.0\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e\u003ch2\u003eDocuments\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/ps-mkt-00443-02-seracare_seraseq_fusion_rna_ref_mat_.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq Fusion RNA Reference Materials (Product Sheet)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/pi-0710-0497-seraseq-fusion-rna-mix-v4.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq Fusion RNA Mix v4 (Package Insert)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/pi-0710-0497--seraseq-fusion-rna-mix-v4.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq Fusion RNA Mix v4 Package Insert (Package Insert)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/tss-0710-0496.0497-seraseq-ffpe-tumor-fusion-rna-v4.xlsx\" target=\"_blank\" rel=\"noopener\"\u003eTechnical Spreadsheet for Seraseq Tumor Fusion RNA v4 Reference Materials (Technical Spreadsheet)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/tss-0710-0497-seraseq-fusion-rna-mix-v4.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq Fusion RNA Mix v4 Technical Spreadsheet (Technical Spreadsheet)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/sds-0710-0497-seraseq-fusion-rna-mix-v4.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSafety Data Sheet for Seraseq Fusion RNA Mix v4 (Safety Data Sheet)\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eOrdering Information\u003c\/h2\u003e\u003ctable\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eCat. no.\u003c\/th\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eSize\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\u003ctr\u003e\n\u003ctd\u003e0710-0497\u003c\/td\u003e\n\u003ctd\u003eSeraseq® Fusion RNA Mix v4\u003c\/td\u003e\n\u003ctd\u003e1 x 25 µL\u003c\/td\u003e\n\u003c\/tr\u003e\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"SeraCare","offers":[{"title":"Default Title","offer_id":46798510129231,"sku":"0710-0497","price":0.0,"currency_code":"ILS","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0712\/0748\/5519\/files\/0710-0497.jpg?v=1789655814"},{"product_id":"seracare-seraseq-ctdna-complete-reference-material-0710-0669","title":"Seraseq® ctDNA Complete™ Reference Material","description":"\u003cp\u003eTo further accelerate the validation and clinical application of liquid biopsy-based ccfDNA targeted NGS assays, SeraCare has developed the Seraseq ctDNA Complete that expands coverage of all relevant variant types (SNVs, INDELs, CNVs, and gene fusions) in a single, highly multiplexed reference sample. These new products are offered in either a purified ctDNA format or a plasma-like matrix format, all precisely quantitated by digital PCR against a single well-characterized genomic background (GM24385), and orthogonally validated with NGS technology.\u003c\/p\u003e\u003cp\u003e\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003e25 unique multiplexed variants in 16 genes, covering 12 SNVs, 7 INDELs, 3 CNVs, and 3 SVs, in purified and plasma-like matrix formats\u003c\/li\u003e\n\u003cli\u003e6 different allele frequencies (AF) – WT, 0.1%, 0.5%, 1%, 2.5% and 5%\u003c\/li\u003e \u003cli\u003eAllows end-to-end evaluation of assay performance across the entire workflow, including pre-analytic extraction steps\u003c\/li\u003e\n\u003cli\u003eVariants quantitated with digital PCR and orthogonally validated by NGS\u003c\/li\u003e\n\u003cli\u003eBlends with well-characterized GM24385 human genomic DNA as background ‘wild-type’ material\u003c\/li\u003e\n\u003cli\u003eManufactured within cGMP compliant, ISO 9001 and ISO 13485 certified facilities\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eSpecifications\u003c\/h2\u003e\u003ctable\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e# of Variants\u003c\/td\u003e\n\u003ctd\u003e25\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFragment Size\u003c\/td\u003e\n\u003ctd\u003e~170bp average\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eConcentration\u003c\/td\u003e\n\u003ctd\u003e25 ng\/mL\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFill Volume\u003c\/td\u003e\n\u003ctd\u003e5 mL\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAmount\u003c\/td\u003e\n\u003ctd\u003e125 ng (single vial)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMatrix\u003c\/td\u003e\n\u003ctd\u003eSeraCon™ Matribase (human plasma-like)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e\u003ch2\u003eDocuments\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/pi-0710-0669.0670.0671.0672.0673.0674-seraseq-ctdna-complete-rm.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq ctDNA Complete Reference Materials Package Insert (Package Insert)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/tss-0710-0528.0529.0530.0531.0532.0533seraseq-ctdna-complete-mutation-mix-technical-spreadsheet.xlsx\" target=\"_blank\" rel=\"noopener\"\u003eTechnical Spreadhseet for Seraseq ctDNA Complete Mutation Mix and Reference Material (Technical Spreadsheet)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/nrl-0710-0669-0674-seraseq-ctdna-complete-reference-material.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq ctDNA Complete Reference Material Non-Requirement Letter (SDS Non-Requirement Letter)\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eOrdering Information\u003c\/h2\u003e\u003ctable\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eCat. no.\u003c\/th\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eSize\u003c\/th\u003e\n\u003cth\u003eAllele Frequency\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e0710-0669\u003c\/td\u003e\n\u003ctd\u003eSeraseq® ctDNA Complete™ Reference Material AF5%\u003c\/td\u003e\n\u003ctd\u003e1 x 5 mL\u003c\/td\u003e\n\u003ctd\u003e5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e0710-0670\u003c\/td\u003e\n\u003ctd\u003eSeraseq® ctDNA Complete™ Reference Material AF2.5%\u003c\/td\u003e\n\u003ctd\u003e1 x 5 mL\u003c\/td\u003e\n\u003ctd\u003e2.5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e0710-0671\u003c\/td\u003e\n\u003ctd\u003eSeraseq® ctDNA Complete™ Reference Material AF1%\u003c\/td\u003e\n\u003ctd\u003e1 x 5 mL\u003c\/td\u003e\n\u003ctd\u003e1%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e0710-0672\u003c\/td\u003e\n\u003ctd\u003eSeraseq® ctDNA Complete™ Reference Material AF0.5%\u003c\/td\u003e\n\u003ctd\u003e1 x 5 mL\u003c\/td\u003e\n\u003ctd\u003e0.5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e0710-0673\u003c\/td\u003e\n\u003ctd\u003eSeraseq® ctDNA Complete™ Reference Material AF0.1%\u003c\/td\u003e\n\u003ctd\u003e1 x 5 mL\u003c\/td\u003e\n\u003ctd\u003e0.1%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e0710-0674\u003c\/td\u003e\n\u003ctd\u003eSeraseq™ ctDNA Complete™ Reference Material WT (0%)\u003c\/td\u003e\n\u003ctd\u003e1 x 5 mL\u003c\/td\u003e\n\u003ctd\u003eWT\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"SeraCare","offers":[{"title":"AF5%","offer_id":46798510424143,"sku":"0710-0669","price":0.0,"currency_code":"ILS","in_stock":true},{"title":"AF2.5%","offer_id":46798510456911,"sku":"0710-0670","price":0.0,"currency_code":"ILS","in_stock":true},{"title":"AF1%","offer_id":46798510489679,"sku":"0710-0671","price":0.0,"currency_code":"ILS","in_stock":true},{"title":"AF0.5%","offer_id":46798510522447,"sku":"0710-0672","price":0.0,"currency_code":"ILS","in_stock":true},{"title":"AF0.1%","offer_id":46798510555215,"sku":"0710-0673","price":0.0,"currency_code":"ILS","in_stock":true},{"title":"WT","offer_id":46798510587983,"sku":"0710-0674","price":0.0,"currency_code":"ILS","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0712\/0748\/5519\/files\/0710-0669.jpg?v=1789655820"},{"product_id":"seracare-seraseq-ctdna-complete-mutation-mix-0710-0528","title":"Seraseq® ctDNA Complete™ Mutation Mix","description":"\u003cp\u003eTo further accelerate the validation and clinical application of liquid biopsy-based ccfDNA-targeted NGS assays, SeraCare has developed the Seraseq ctDNA Complete that expands coverage of all relevant variant types including SNVs, INDELs, CNVs, and gene fusions in a single highly-multiplexed reference sample. These new products are offered in either a purified ctDNA format or a plasma-like matrix format, all precisely quantitated by digital PCR against a single well-characterized genomic background (GM24385), and orthogonally validated with NGS technology.\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003e25 unique multiplexed variants in 16 genes, covering 12 SNVs, 7 INDELs, 3 CNVs, and 3 SVs, in purified and plasma-like matrix formats.\u003c\/li\u003e\n\u003cli\u003e6 different allele frequencies available: wild-type, 0.1%, 0.5%, 1%, 2.5%, and 5%\u003c\/li\u003e\n\u003cli\u003eAllows end-to-end evaluation of assay performance across the entire workflow, including pre-analytic extraction steps\u003c\/li\u003e\n\u003cli\u003eVariants quantitated with digital PCR and orthogonally validated by NGS\u003c\/li\u003e\n\u003cli\u003eBlends with well-characterized GM24385 human genomic DNA as background wild-type material\u003c\/li\u003e\n\u003cli\u003eManufactured within cGMP-compliant and ISO 13485-certified facilities.\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eSpecifications\u003c\/h2\u003e\u003ctable\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e# of Variants\u003c\/td\u003e\n\u003ctd\u003e25\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFragment Size\u003c\/td\u003e\n\u003ctd\u003e~170bp\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eConcentration\u003c\/td\u003e\n\u003ctd\u003e10ng\/µL\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFill Volume\u003c\/td\u003e\n\u003ctd\u003e25 µL\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal DNA\u003c\/td\u003e\n\u003ctd\u003e250 ng\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBuffer\u003c\/td\u003e\n\u003ctd\u003eTris\/EDTA (TE)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e\u003ch2\u003eDocuments\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/ps-seraseq-ctdna-complete-reference-materials.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq® ctDNA Complete™ Reference Materials Product Sheet (Product Sheet)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/pi-0710-0528-thru-0533-seraseq-ctdna-complete-mutation-mix.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq ctDNA Complete Mutation Mix AF5%, AF2.5%, AF1%, AF0.5%, AF0.1%, WT (Wild-Type) (Package Insert)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/tss-0710-0528.0529.0530.0531.0532.0533seraseq-ctdna-complete-mutation-mix-technical-spreadsheet.xlsx\" target=\"_blank\" rel=\"noopener\"\u003eTechnical Spreadhseet for Seraseq ctDNA Complete Mutation Mix and Reference Material (Technical Spreadsheet)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/nrl-0710-0528-0533-seraseq-complete-mutation-mix.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq ctDNA Complete Mutation Mix Non-Requirement Letter (SDS Non-Requirement Letter)\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eOrdering Information\u003c\/h2\u003e\u003ctable\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eCat. no.\u003c\/th\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eSize\u003c\/th\u003e\n\u003cth\u003eAllele Frequency\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e0710-0528\u003c\/td\u003e\n\u003ctd\u003eSeraseq® ctDNA Complete™ Mutation Mix AF5%\u003c\/td\u003e\n\u003ctd\u003e1 x 25 µL\u003c\/td\u003e\n\u003ctd\u003e5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e0710-0529\u003c\/td\u003e\n\u003ctd\u003eSeraseq® ctDNA Complete™ Mutation Mix AF2.5%\u003c\/td\u003e\n\u003ctd\u003e1 x 25 µL\u003c\/td\u003e\n\u003ctd\u003e2.5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e0710-0530\u003c\/td\u003e\n\u003ctd\u003eSeraseq® ctDNA Complete™ Mutation Mix AF1%\u003c\/td\u003e\n\u003ctd\u003e1 x 25 µL\u003c\/td\u003e\n\u003ctd\u003e1%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e0710-0531\u003c\/td\u003e\n\u003ctd\u003eSeraseq® ctDNA Complete™ Mutation Mix AF0.5%\u003c\/td\u003e\n\u003ctd\u003e1 x 25 µL\u003c\/td\u003e\n\u003ctd\u003e0.5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e0710-0532\u003c\/td\u003e\n\u003ctd\u003eSeraseq® ctDNA Complete™ Mutation Mix AF0.1%\u003c\/td\u003e\n\u003ctd\u003e1 x 25 µL\u003c\/td\u003e\n\u003ctd\u003e0.1%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e0710-0533\u003c\/td\u003e\n\u003ctd\u003eSeraseq® ctDNA Complete™ Mutation Mix WT (0%)\u003c\/td\u003e\n\u003ctd\u003e1 x 25 µL\u003c\/td\u003e\n\u003ctd\u003eWild Type\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"SeraCare","offers":[{"title":"AF5%","offer_id":46798510227535,"sku":"0710-0528","price":0.0,"currency_code":"ILS","in_stock":true},{"title":"AF2.5%","offer_id":46798510260303,"sku":"0710-0529","price":0.0,"currency_code":"ILS","in_stock":true},{"title":"AF1%","offer_id":46798510293071,"sku":"0710-0530","price":0.0,"currency_code":"ILS","in_stock":true},{"title":"AF0.5%","offer_id":46798510325839,"sku":"0710-0531","price":0.0,"currency_code":"ILS","in_stock":true},{"title":"AF0.1%","offer_id":46798510358607,"sku":"0710-0532","price":0.0,"currency_code":"ILS","in_stock":true},{"title":"WT","offer_id":46798510391375,"sku":"0710-0533","price":0.0,"currency_code":"ILS","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0712\/0748\/5519\/files\/0710-0528.jpg?v=1789655820"},{"product_id":"seracare-seraseq-ffpe-ntrk-fusion-rna-reference-material-0710-1031","title":"Seraseq® FFPE NTRK Fusion RNA Reference Material","description":"\u003cp\u003eNeurotrophic tyrosine receptor kinases (NTRK) can become abnormally fused to other genes resulting in growth signals that can lead to cancer in many organs of the human body. Anti-tumor drugs that target NTRK fusions have been shown to be largely effective across many tumor types regardless of patient age (adult or pediatric), especially in locally advanced or metastatic solid tumors. This product expands SeraCare's RNA Fusion FFPE reference material product portfolio to support routine clinical diagnostic \/ companion diagnostic (CDx) use for solid tumor testing of tissue biopsies for NTRK fusion genes in cancer disease diagnosis and treatment selection.\u003c\/p\u003e\u003cp\u003e\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003e15 clinically-relevant NTRK fusion genes in a single reference sample\u003c\/li\u003e\n\u003cli\u003eOffered as FFPE for full process assay (NGS or PCR) workflow monitoring and patient testing\u003c\/li\u003e\n\u003cli\u003eFusions precisely quantitated with digital PCR\u003c\/li\u003e\n\u003cli\u003eWell-characterized GM24385 human genomic RNA as background wild-type material\u003c\/li\u003e\n\u003cli\u003eManufactured in GMP-compliant and ISO 13485-certified facilities\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eDocuments\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/ps-mkt-00538-01_seracare-seraseq_ntrk_fusion_rna_refmat.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq NTRK Fusion RNA Reference Materials (Product Sheet)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/pi-0710-1031-seraseq-ffpe-ntrk-fusion-rna-rm-sep2018.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq FFPE NTRK Fusion RNA Reference Material (Package Insert)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/tss-0710-1031.1696-seraseq-ffpe-ntrk-fusion-rna-rm_technical-spreadsheet.xlsx\" target=\"_blank\" rel=\"noopener\"\u003eTechnical Spreadsheet for Seraseq NTRK Fusion RNA Reference Materials (Technical Spreadsheet)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/sds-seraseq-ffpe.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq FFPE Safety Data Sheet (Safety Data Sheet)\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eOrdering Information\u003c\/h2\u003e\u003ctable\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eCat. no.\u003c\/th\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eSize\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\u003ctr\u003e\n\u003ctd\u003e0710-1031\u003c\/td\u003e\n\u003ctd\u003eSeraseq® FFPE NTRK Fusion RNA Reference Material\u003c\/td\u003e\n\u003ctd\u003e1 x 10 µm\u003c\/td\u003e\n\u003c\/tr\u003e\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"SeraCare","offers":[{"title":"Default Title","offer_id":46798510850127,"sku":"0710-1031","price":0.0,"currency_code":"ILS","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0712\/0748\/5519\/files\/0710-1031.jpg?v=1789655827"},{"product_id":"seracare-seraseq-ffpe-tmb-reference-material-0710-1310","title":"Seraseq® FFPE TMB Reference Material","description":"\u003cp\u003eIn immuno-oncology, the goal is to enable a patient’s immune system to locate and eliminate cancerous cells. The immune system may normally protect against cancer – except, when cancers manage to evade it – since immunocompromised individuals have a higher likelihood of developing cancer. Checkpoint inhibitors, which have recently improved the prognosis for a significant number of cancer patients, work by blocking inhibitory molecules such as PD-L1 and CTLA-4 that may be allowing cancers to evade the adaptive immune system. However, by taking the brakes off the immune system, the use of checkpoint inhibitors is associated with a significant risk of developing autoimmune disease. Additionally, frequently checkpoint inhibitors are not effective.\u003c\/p\u003e\u003cp\u003eIn order to maximize the safety and efficacy of checkpoint inhibitors, it is beneficial to identify patients who are likely to respond to their use. Since the adaptive immune system can detect changes to proteins, it is thought that the number of somatic mutations that lead to such changes may be correlated with efficacy. The metric of non-silent somatic mutations per megabase of coding DNA has been termed tumor mutational burden (TMB), which has shown some correlation to the efficacy of checkpoint inhibitors. Assessments of TMB are being added to many NGS assays order to enable their use for patient selection for clinical trials and perhaps later as companion diagnostics. However, it is also known that TMB scores can differ significantly between assays and especially around levels that may be clinical decision points.\u003c\/p\u003e\u003cp\u003eTo improve and harmonize the measurement of TMB, we have generated and characterized tumor-normal human cell lines with different TMB scores for whole exome sequencing analysis of TMB in patient samples, for validating targeted NGS panel-based TMB assays, and as controls for TMB measurements in I-O clinical trial projects.\u003c\/p\u003e\u003cp\u003eThe TMB reference materials are available as genomic DNA (purified mix) format and\/or FFPE (require extraction) format, as tumor-normal standards.\u003c\/p\u003e\u003cp\u003eFFPE TMB Reference Standards:\u003cbr\u003eReference standards are made from human lung cancer cell lines at 30% tumor content, formalin-treated and paraffin-embedded into FFPE blocks, which are then cut into 10 µm sections.\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003e30% tumor-normal FFPE reference standards\u003c\/li\u003e\n\u003cli\u003ecompatible with a range of FFPE extraction kits\u003c\/li\u003e\n\u003cli\u003erange of TMB scores\u003c\/li\u003e\n\u003cli\u003emanufactured in GMP-compliant and ISO 13485 certified facilities\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eSpecifications\u003c\/h2\u003e\u003ctable\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSize\u003c\/td\u003e\n\u003ctd\u003e10 µm\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFormat\u003c\/td\u003e\n\u003ctd\u003eFFPE\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e\u003ch2\u003eDocuments\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/PS-MKT-00504-04-0710-1326.0710-1325.0710-1586.0710-1324.0710-1323.0710-2087.0710-2088.0710-2089.0710-2090.0710-1310.0710-1308.0710-1618.0710-1309.0710-1307.Seraseq_gDNA_ctDNA_and_FFPE_TMB_Products.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq gDNA, ctDNA and FFPE TMB Product Sheet (Product Sheet)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/ds-0710-13070710-13080710-13090710-1310-seraseq-ffpe-tmb-rm-score-7-9-20-26.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq FFPE TMB RM (Data Sheet)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/pi-0710-1307.1308.1309.1310-seraseq-ffpe-tmb-rm.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq FFPE TMB RM Products (Package Insert)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/sds-seraseq-ffpe.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq FFPE Safety Data Sheet (Safety Data Sheet)\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eOrdering Information\u003c\/h2\u003e\u003ctable\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eCat. no.\u003c\/th\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eSize\u003c\/th\u003e\n\u003cth\u003eTMB Score\u003c\/th\u003e\n\u003cth\u003eDNA Yield\u003c\/th\u003e\n\u003cth\u003eDNA Yeild\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e0710-1310\u003c\/td\u003e\n\u003ctd\u003eSeraseq® FFPE TMB RM Score 7\u003c\/td\u003e\n\u003ctd\u003e2 x 10 µm\u003c\/td\u003e\n\u003ctd\u003e7.2 ± 0.4 #\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;100 ng\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e0710-1308\u003c\/td\u003e\n\u003ctd\u003eSeraseq® FFPE TMB RM Score 9\u003c\/td\u003e\n\u003ctd\u003e2 x 10 µm\u003c\/td\u003e\n\u003ctd\u003e7.5\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;100 ng\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e0710-1618\u003c\/td\u003e\n\u003ctd\u003eSeraseq® FFPE TMB RM Score 13\u003c\/td\u003e\n\u003ctd\u003e2 x 10 µm\u003c\/td\u003e\n\u003ctd\u003e12.1 ± 0.3 #\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;100 ng\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e0710-1309\u003c\/td\u003e\n\u003ctd\u003eSeraseq® FFPE TMB RM Score 20\u003c\/td\u003e\n\u003ctd\u003e2 x 10 µm\u003c\/td\u003e\n\u003ctd\u003e18.6 ± 0.5 #\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;100 ng\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e0710-1307\u003c\/td\u003e\n\u003ctd\u003eSeraseq® FFPE TMB RM Score 26\u003c\/td\u003e\n\u003ctd\u003e2 x 10 µm\u003c\/td\u003e\n\u003ctd\u003e22.8 ± 3.6 #\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;100 ng\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"SeraCare","offers":[{"title":"Score 7","offer_id":46798510686287,"sku":"0710-1310","price":0.0,"currency_code":"ILS","in_stock":true},{"title":"Score 9","offer_id":46798510719055,"sku":"0710-1308","price":0.0,"currency_code":"ILS","in_stock":true},{"title":"Score 13","offer_id":46798510751823,"sku":"0710-1618","price":0.0,"currency_code":"ILS","in_stock":true},{"title":"Score 20","offer_id":46798510784591,"sku":"0710-1309","price":0.0,"currency_code":"ILS","in_stock":true},{"title":"Score 26","offer_id":46798510817359,"sku":"0710-1307","price":0.0,"currency_code":"ILS","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0712\/0748\/5519\/files\/0710-1310.jpg?v=1789655827"},{"product_id":"seracare-seraseq-gdna-tmb-mix-0710-1326","title":"Seraseq® gDNA TMB Mix","description":"\u003cp\u003eIn immuno-oncology, the goal is to enable a patient’s immune system to locate and eliminate cancerous cells. The immune system may normally protect against cancer – except when cancers manage to evade it – since immunocompromised individuals have a higher likelihood of developing cancer. Checkpoint inhibitors, which have recently improved the prognosis for a significant number of cancer patients, work by blocking inhibitory molecules such as PD-L1 and CTLA-4 that may be allowing cancers to evade the adaptive immune system. However, by taking the brakes off the immune system, the use of checkpoint inhibitors is associated with a significant risk of developing autoimmune disease. Additionally, frequently checkpoint inhibitors are not effective.\u003c\/p\u003e\u003cp\u003eIn order to maximize the safety and efficacy of checkpoint inhibitors, it is beneficial to identify patients who are likely to respond to their use. Since the adaptive immune system can detect changes to proteins, it is thought that the number of somatic mutations that lead to such changes may be correlated with efficacy. The metric of non-silent somatic mutations per megabase of coding DNA has been termed Tumor Mutational Burden (TMB), which has shown some correlation to the efficacy of checkpoint inhibitors. Assessments of TMB are being added to many NGS assays to enable their use for patient selection in I-O clinical trials, and perhaps as companion diagnostics to these therapies. However, it is also known that TMB scores can differ significantly between assays and especially around levels that may be clinical decision points.\u003c\/p\u003e\u003cp\u003eTo improve and harmonize the measurement of TMB, we have generated and characterized tumor-normal human cell lines with different TMB scores by whole exome sequencing for use in validating targeted NGS panel-based TMB assays, and as controls for TMB measurements in I-O clinical trial projects.\u003c\/p\u003e\u003cp\u003eThe TMB reference materials are formated as genomic DNA (purified mix) and\/or FFPE (requires extraction).\u003c\/p\u003e\u003cp\u003egDNA TMB Reference Standards:\u003cbr\u003eReference standards are made from human lung cancer cell lines and their matched “normal” cell lines from peripheral blood of the same patients.\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003e100% tumor-normal matched reference standards\u003c\/li\u003e\n\u003cli\u003epurified gDNA mix, ready as input into WES or targeted NGS library preparation\u003c\/li\u003e\n\u003cli\u003erange of TMB scores\u003c\/li\u003e\n\u003cli\u003emanufactured in GMP-compliant and ISO 13485 certified facilities\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eSpecifications\u003c\/h2\u003e\u003ctable\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFill Volume\u003c\/td\u003e\n\u003ctd\u003e10 µL\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eConcentration\u003c\/td\u003e\n\u003ctd\u003e50 ng\/µl\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e\u003ch2\u003eDocuments\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/PS-MKT-00504-04-0710-1326.0710-1325.0710-1586.0710-1324.0710-1323.0710-2087.0710-2088.0710-2089.0710-2090.0710-1310.0710-1308.0710-1618.0710-1309.0710-1307.Seraseq_gDNA_ctDNA_and_FFPE_TMB_Products.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq gDNA, ctDNA and FFPE TMB Product Sheet (Product Sheet)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/ds-0710-13230710-13240710-13250710-1326-seraseq-gdna-tmb-mix-score-7-9-20-26.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq gDNA TMB Mix (Data Sheet)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/pi-0710-1323.1324.1325.1326-seraseq-gdna-ffpe-tmb-mix.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq gDNA TMB Mix Products (Package Insert)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/nrl-0710-2463.1326.1325-seraseq-gdna-tmb.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq gDNA TMB Non-Requirement Letter (SDS Non-Requirement Letter)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/nrl-0710-1586.1324.1323seraseq-gdna-mix.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq gDNA TMB Mix Score Non-Requirement Letter (SDS Non-Requirement Letter)\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eOrdering Information\u003c\/h2\u003e\u003ctable\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eCat. no.\u003c\/th\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eSize\u003c\/th\u003e\n\u003cth\u003eTMB Score\u003c\/th\u003e\n\u003cth\u003eTotal Mass\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e0710-1326\u003c\/td\u003e\n\u003ctd\u003eSeraseq® gDNA TMB Mix Score 7\u003c\/td\u003e\n\u003ctd\u003e2 x 500 ng\u003c\/td\u003e\n\u003ctd\u003e7.2 ± 0.2*\u003c\/td\u003e\n\u003ctd\u003e2 x 500 ng\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e0710-1325\u003c\/td\u003e\n\u003ctd\u003eSeraseq® gDNA TMB Mix Score 9\u003c\/td\u003e\n\u003ctd\u003e2 x 500 ng\u003c\/td\u003e\n\u003ctd\u003e9.5 ± 0.4\u003c\/td\u003e\n\u003ctd\u003e2 x 500 ng\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e0710-1586\u003c\/td\u003e\n\u003ctd\u003eSeraseq® gDNA TMB Mix Score 13\u003c\/td\u003e\n\u003ctd\u003e2 x 10 µL\u003c\/td\u003e\n\u003ctd\u003e12.6 ± 0.02*\u003c\/td\u003e\n\u003ctd\u003e2x 500 ng\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e0710-1324\u003c\/td\u003e\n\u003ctd\u003eSeraseq® gDNA TMB Mix Score 20\u003c\/td\u003e\n\u003ctd\u003e2 x 500 ng\u003c\/td\u003e\n\u003ctd\u003e20.1 ± 0.2*\u003c\/td\u003e\n\u003ctd\u003e2 x 500 ng\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e0710-1323\u003c\/td\u003e\n\u003ctd\u003eSeraseq® gDNA TMB Mix Score 26\u003c\/td\u003e\n\u003ctd\u003e2 x 500 ng\u003c\/td\u003e\n\u003ctd\u003e25.8 ± 0.5*\u003c\/td\u003e\n\u003ctd\u003e2 x 500 ng\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"SeraCare","offers":[{"title":"Score 7","offer_id":46798510948431,"sku":"0710-1326","price":0.0,"currency_code":"ILS","in_stock":true},{"title":"Score 9","offer_id":46798510981199,"sku":"0710-1325","price":0.0,"currency_code":"ILS","in_stock":true},{"title":"Score 13","offer_id":46798511013967,"sku":"0710-1586","price":0.0,"currency_code":"ILS","in_stock":true},{"title":"Score 20","offer_id":46798511046735,"sku":"0710-1324","price":0.0,"currency_code":"ILS","in_stock":true},{"title":"Score 26","offer_id":46798511079503,"sku":"0710-1323","price":0.0,"currency_code":"ILS","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0712\/0748\/5519\/files\/0710-1326.jpg?v=1789655832"},{"product_id":"seracare-seraseq-compromised-ffpe-tumor-dna-reference-material-0710-1492","title":"Seraseq® Compromised FFPE Tumor DNA Reference Material","description":"\u003cp\u003eComprehensive genomic profiling (CGP) is an important part of an integrated clinical management of cancer patients, where cancer patients harboring variants\/biomarkers of clinical utility are determined by highly multiplexed targeted NGS assay testing. Precise analysis of these patient samples requires high quality sample-to-result assay workflow controls to guide and validate the accurate identification of these actionable variants.\u003c\/p\u003e\u003cp\u003eLGC SeraCare has developed a highly multiplexed Compromised FFPE Tumor DNA reference material imbibing “patient-like” characteristics to support end-to-end NGS workflows performed by clinical labs in the analysis of cancer patient samples. This product consists of 17 genes and 34 variants, incorporating all variant types – SNVs, INDELs, CNVs, and SVs. These variants were precisely quantitated by digital PCR and targeted NGS against a single well-characterized genomic background (GM24385).\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eHighly multiplexed FFPE Tumor DNA reference material\u003c\/li\u003e\n\u003cli\u003eContains 34 variants in 17 genes\u003c\/li\u003e\n\u003cli\u003eAll variant types – SNVs (18), INDELs (10), CNVs (3) and SVs (3)\u003c\/li\u003e\n\u003cli\u003eFor use in sample-to-result NGS workflows to analyze for mutation-positive variants in patient samples\u003c\/li\u003e\n\u003cli\u003eManufactured in GMP-compliant ISO 13485 certified facility\u003c\/li\u003e\n\u003c\/ul\u003e\u003ctable\u003e\u003ctbody\u003e\n\u003ctr\u003e\u003ctd colspan=\"4\"\u003e\u003cstrong\u003eGene List\u003c\/strong\u003e\u003c\/td\u003e\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eATK1\u003c\/td\u003e\n\u003ctd\u003eEGFR\u003c\/td\u003e\n\u003ctd\u003eMYC\u003c\/td\u003e\n\u003ctd\u003eCD74-ROSI\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eALK\u003c\/td\u003e\n\u003ctd\u003eERBB2\u003c\/td\u003e\n\u003ctd\u003eNRAS\u003c\/td\u003e\n\u003ctd\u003eNCOA4-RET\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBRAF\u003c\/td\u003e\n\u003ctd\u003eKIT\u003c\/td\u003e\n\u003ctd\u003ePIK3CA\u003c\/td\u003e\n\u003ctd\u003eEML4-ALK\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBRCA1\u003c\/td\u003e\n\u003ctd\u003eKRAS\u003c\/td\u003e\n\u003ctd\u003eTP53\u003c\/td\u003e\n\u003ctd\u003e \u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBRCA2\u003c\/td\u003e\n\u003ctd\u003eMET\u003c\/td\u003e\n\u003ctd\u003e \u003c\/td\u003e\n\u003ctd\u003e \u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e\u003ch2\u003eSpecifications\u003c\/h2\u003e\u003ctable\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e# of genes\u003c\/td\u003e\n\u003ctd\u003e17\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSize\u003c\/td\u003e\n\u003ctd\u003e10 µm\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFormat\u003c\/td\u003e\n\u003ctd\u003eFFPE\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDNA Yield\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;100 ng*\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e\u003ch2\u003eDocuments\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/pi-0710-1492-seraseq-compromised-ffpe-tumor-dna-rm.pdf\" target=\"_blank\" rel=\"noopener\"\u003ePackage Insert for Seraseq® Compromised FFPE Tumor DNA RM (Package Insert)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/tss-0710-1492-seraseq-compromised-ffpe-tumor-dna-rm.xlsx\" target=\"_blank\" rel=\"noopener\"\u003eTechnical Spreadsheet for Seraseq Compromised FFPE Tumor DNA RM (Technical Spreadsheet)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/sds-seraseq-ffpe.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq FFPE Safety Data Sheet (Safety Data Sheet)\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eOrdering Information\u003c\/h2\u003e\u003ctable\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eCat. no.\u003c\/th\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eSize\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\u003ctr\u003e\n\u003ctd\u003e0710-1492\u003c\/td\u003e\n\u003ctd\u003eSeraseq® Compromised FFPE Tumor DNA RM\u003c\/td\u003e\n\u003ctd\u003e1 x 10 µm\u003c\/td\u003e\n\u003c\/tr\u003e\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"SeraCare","offers":[{"title":"Default Title","offer_id":46798511145039,"sku":"0710-1492","price":0.0,"currency_code":"ILS","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0712\/0748\/5519\/files\/0710-1492.jpg?v=1789655833"},{"product_id":"seracare-seraseq-tna-dna-rna-wt-mix-0710-1580","title":"Seraseq® TNA (DNA\/RNA) WT Mix","description":"\u003cp\u003eMolecular assays that profile tumor mutations in solid tissue biopsies require an efficient and precise evaluation of the pre-analytic portion of their workflow prior to downstream analysis by NGS or other methods. The use of contrived reference material or cell line-based control provides a critical input to the optimization of nucleic acid extraction from very challenging FFPE tissue materials without wasting precious mutation-positive tissue samples.\u003c\/p\u003e\u003cp\u003eWe have developed two formats of total nucleic acid (TNA) derived from GM24385 human cell line as negative sample reference materials for use in targeted NGS assays. The cell line is applied as the WT background in all existing Seraseq tumor DNA and RNA products. As a negative reference material, we have extracted DNA and RNA from GM24385 as a buffered mix (TNA WT) as well as a formalin fixed and paraffin embedded option (FFPE curls) to support labs validating assay specificity at wildtype base positions, as well as specificity at positions affected by mutations included in all of the Seraseq RNA and DNA (Mutation Mix and Reference Material) products.\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eCell line-based negative (WT) sample reference material\u003c\/li\u003e\n\u003cli\u003eOffered as purified and ready-to-use RNA and DNA (up to 1 µg) in targeted NGS assay workflows\u003c\/li\u003e\n\u003cli\u003eWell characterized GM 24385 wild-type human cell line material\u003c\/li\u003e\n\u003cli\u003eManufactured in GMP-compliant ISO 13485 certified facility\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eSpecifications\u003c\/h2\u003e\u003ctable\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eConcentration\u003c\/td\u003e\n\u003ctd\u003e2 x 25 ng\/ul\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFill Volume\u003c\/td\u003e\n\u003ctd\u003e2 x 20 µL\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDNA Size\u003c\/td\u003e\n\u003ctd\u003e500 ng\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRNA Size\u003c\/td\u003e\n\u003ctd\u003e500 ng\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e\u003ch2\u003eDocuments\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/ps-mkt-00525_seraseq-total-nucleic-acid-reference-materials.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq Total Nucleic Acid (Product Sheet)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/onc-060-mkt-00525-ps-seraseq-tna-reference-materials.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq Total Nucleic Acid Reference Materials (Product Sheet)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/pi-0710-1580-seraseq-tna-wt-mix.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq TNA Wild Type Mix (Package Insert)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/nrl-0710-1580-seraseq-tna.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq TNA (DNA\/RNA) Non-Requirement Letter (SDS Non-Requirement Letter)\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eOrdering Information\u003c\/h2\u003e\u003ctable\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eCat. no.\u003c\/th\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eSize\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\u003ctr\u003e\n\u003ctd\u003e0710-1580\u003c\/td\u003e\n\u003ctd\u003eSeraseq® TNA (DNA\/RNA) WT Mix\u003c\/td\u003e\n\u003ctd\u003e2 x 20 µL\u003c\/td\u003e\n\u003c\/tr\u003e\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"SeraCare","offers":[{"title":"Default Title","offer_id":46798511177807,"sku":"0710-1580","price":0.0,"currency_code":"ILS","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0712\/0748\/5519\/files\/0710-1580.jpg?v=1789655838"},{"product_id":"seracare-seraseq-gdna-msi-high-mix-0710-1670","title":"Seraseq® gDNA MSI-High Mix","description":"\u003cp\u003eINTRODUCTION\u003c\/p\u003e\u003cp\u003eMicrosatellites are regions of DNA repeats with different lengths, i.e., instability, highlighting DNA mismatch repair gene deficiencies. Typical repeat units are between 1-6 base pairs and the number of repeats vary from person to person such that each person has a set length of these microsatellites in their genome. Measurements of MSI have traditionally been performed using qPCR\/CE fragment length analysis methods, or immunohistochemistry (IHC), but new methodologies such as digital droplet PCR (ddPCR) and Next Generation Sequencing (NGS) are now being applied to determination of MSI status of cancer patients. High incidence of microsatellite instability (MSI) has been linked to favorable outcomes in immuno-oncology (I-O) treatment response by patients with diseases such as Lynch Syndrome and colorectal cancer. Hence determination of MSI status for cancer patients is important in I-O therapeutics management.\u003c\/p\u003e\u003cp\u003eLGC SeraCare has developed microsatellite instability (MSI) reference materials that support qPCR and NGS assays that target a range of short tandem repeat regions commonly analyzed for microsatellite instabilities. For assays that target specific mono and dinucleotide repeats such as BAT-25, BAT-26, NR-21, NR-24, MONO-27, we have created MSI reference materials containing these markers blended at two different allele frequency (AF) levels – 5% and 20%. Additionally, for NGS MSI assays that analyze for a large number of microsatellite loci across the human genome, we have a human diseased cell line-based MSI-High reference material for such analysis. These products are quantitated by PCR (qPCR\/CE and ddPCR) and by targeted NGS assays to support all product claims.\u003c\/p\u003e\u003cp\u003e\u003cbr\u003eFEATURES AND BENEFITS\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eCell line or plasmid-based MSI reference material mix for analysis in molecular assays or NGS\u003c\/li\u003e\n\u003cli\u003eOffered as tumor-only (MSI-High) or tumor-normal (AF5% and AF20%) options\u003c\/li\u003e\n\u003cli\u003eSupport MSI assay validation, LoD determination, and routine detection of MSI markers in cancer patient samples\u003c\/li\u003e\n\u003cli\u003eVariant AFs (AF5% and AF20% products) quantitated by ddPCR and qPCR\/CE fragment length analysis assays\u003c\/li\u003e\n\u003cli\u003eNormal background DNA is a highly characterized GM24385 human genomic DNA known to be microsatellite stable (MSS)\u003c\/li\u003e\n\u003cli\u003eManufactured within cGMP compliant and ISO 13485 certified facilities\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eSpecifications\u003c\/h2\u003e\u003ctable\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e# of Variants\u003c\/td\u003e\n\u003ctd\u003eVariable\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAllele Frequency\u003c\/td\u003e\n\u003ctd\u003eVariable\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eConcentration\u003c\/td\u003e\n\u003ctd\u003e25 ng\/µL\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFill Volume\u003c\/td\u003e\n\u003ctd\u003e20 µL\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal DNA\u003c\/td\u003e\n\u003ctd\u003e500 ng\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e# of Vials\u003c\/td\u003e\n\u003ctd\u003e1 (tumor only)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMatrix\u003c\/td\u003e\n\u003ctd\u003eTE Buffer\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e\u003ch2\u003eDocuments\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/ps-mkt-00534_0710-1670.0710-2236.0710-1675.0710-1676_seraseq_msi-reference_materials.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq MSI Reference Materials Product Sheet (Product Sheet)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/ds-mkt-00555-0710-16700710-16750710-1676-seraseq_msi_reference_materials_fnl-4.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq MSI Reference Materials (Data Sheet)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/pi-0710-1670-seraseq-gdna-msi-high-mix.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq gDNA MSI-High Mix 0710-1670 (Package Insert)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/nrl-0710-1670-seraseq-gdna-msi.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq gDNA MSI-High Mix Non-Requirement Letter (SDS Non-Requirement Letter)\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eOrdering Information\u003c\/h2\u003e\u003ctable\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eCat. no.\u003c\/th\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eSize\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\u003ctr\u003e\n\u003ctd\u003e0710-1670\u003c\/td\u003e\n\u003ctd\u003eSeraseq® gDNA MSI-High Mix\u003c\/td\u003e\n\u003ctd\u003e1 x 20 µL\u003c\/td\u003e\n\u003c\/tr\u003e\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"SeraCare","offers":[{"title":"Default Title","offer_id":46798511308879,"sku":"0710-1670","price":0.0,"currency_code":"ILS","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0712\/0748\/5519\/files\/0710-1670.jpg?v=1789655841"},{"product_id":"seracare-seraseq-msi-reference-panel-mix-0710-1676","title":"Seraseq® MSI Reference Panel Mix","description":"\u003cp\u003eMicrosatellites are regions of DNA repeats with different lengths, i.e., instability, highlighting DNA mismatch repair gene deficiencies. Typical lengths for these DNA repeats are between 1-6 base pairs and vary person to person such that each person has a set length of these microsatellites in their genome. Measurements of MSI have traditionally been performed using qPCR\/CE analysis methods, but new methodologies are now available that includes digital droplet PCR (ddPCR) as well as Next Generation Sequencing (NGS). Microsatellite instability status has been linked to favorable outcomes in I-O treatment response by patients with diseases such as Lynch Syndrome and colorectal cancer. Hence MSI measurements have become an important biomarker in immuno-oncology therapeutics.\u003c\/p\u003e\u003cp\u003eLGC SeraCare has developed microsatellite instability (MSI) reference materials containing the key mono- and dinucleotide biomarkers typically analyzed in molecular MSI assays – NR-21, NR-24, BAT-25, BAT-26 and MONO-27. These markers are blended at two different allele frequency levels – AF5% and AF20% - to support MSI assay LoD determinations and accurate MSI detection. These products are offered as tumor-normal matched pairs, with variants precisely quantitated by digital PCR as well as qPCR\/CE against a highly characterized genomic DNA from a background WT cell line (GM24385) determined as microsatellite stable (MSS).\u003c\/p\u003e\u003cp\u003eFEATURES AND BENEFITS\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003ePlasmid-based spike-ins of 5 key MSI biomarkers typically analyzed in molecular assays that measure MSI in cancer patent samples\u003c\/li\u003e\n\u003cli\u003eOffered as tumor-normal matched pairs per AF level\u003c\/li\u003e\n\u003cli\u003eEach biomarker blended at two AF levels – 5% and 20% - to support assay LoD determinations and accurate MSI detection in patient samples\u003c\/li\u003e\n\u003cli\u003eVariant AFs quantitated by ddPCR and qPCR assays\u003c\/li\u003e\n\u003cli\u003eNormal background DNA is a highly characterized GM24385 human genomic DNA known to be microsatellite stable (MSS)\u003c\/li\u003e\n\u003cli\u003eManufactured within cGMP compliant and ISO 13485 certified facilities\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eSpecifications\u003c\/h2\u003e\u003ctable\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e# of Variants\u003c\/td\u003e\n\u003ctd\u003e5\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eConcentration\u003c\/td\u003e\n\u003ctd\u003e20 ng\/µL\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFill Volume\u003c\/td\u003e\n\u003ctd\u003e15 µL\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal DNA\u003c\/td\u003e\n\u003ctd\u003e300 ng\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e# of Vials\u003c\/td\u003e\n\u003ctd\u003e2 (tumor-normal matched)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMatrix\u003c\/td\u003e\n\u003ctd\u003eTE Buffer\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMAP4K3 (intron13)\u003c\/td\u003e\n\u003ctd\u003e39536690\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e\u003ch2\u003eDocuments\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/ps-mkt-00534_0710-1670.0710-2236.0710-1675.0710-1676_seraseq_msi-reference_materials.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq MSI Reference Materials Product Sheet (Product Sheet)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/ds-mkt-00555-0710-16700710-16750710-1676-seraseq_msi_reference_materials_fnl-4.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq MSI Reference Materials (Data Sheet)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/pi-0710-1675.1676-seraseq-msi-ref-panel-mix-af5-af20.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq MSI Reference Panel Mix AF5% and AF20% (Package Insert)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/nrl-0710-1675-1676-seraseq-msi-reference-panel.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq MSI Reference Panel Non-Requirement Letter (SDS Non-Requirement Letter)\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eOrdering Information\u003c\/h2\u003e\u003ctable\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eCat. no.\u003c\/th\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eSize\u003c\/th\u003e\n\u003cth\u003eAllele Frequency\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e0710-1676\u003c\/td\u003e\n\u003ctd\u003eSeraseq® MSI Reference Panel Mix AF20%\u003c\/td\u003e\n\u003ctd\u003e2 x 15 µL\u003c\/td\u003e\n\u003ctd\u003e20%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e0710-1675\u003c\/td\u003e\n\u003ctd\u003eSeraseq® MSI Reference Panel Mix AF5%\u003c\/td\u003e\n\u003ctd\u003e2 x 15 µL\u003c\/td\u003e\n\u003ctd\u003e5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"SeraCare","offers":[{"title":"AF20%","offer_id":46798511341647,"sku":"0710-1676","price":0.0,"currency_code":"ILS","in_stock":true},{"title":"AF5%","offer_id":46798511374415,"sku":"0710-1675","price":0.0,"currency_code":"ILS","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0712\/0748\/5519\/files\/0710-1676.jpg?v=1789655843"},{"product_id":"seracare-seraseq-ntrk-fusion-rna-mix-0710-1696","title":"Seraseq® NTRK Fusion RNA Mix","description":"\u003cp\u003eNeurotrophic tyrosine receptor kinases (NTRK) can become abnormally fused to other genes resulting in growth signals that can lead to cancer in many organs of the human body. Anti-tumor drugs that target NTRK fusions have been shown to be largely effective across many tumor types regardless of patient age (adult or pediatric), especially in locally advanced or metastatic solid tumors. This product expands SeraCare's RNA Fusion FFPE reference material product portfolio to support routine clinical diagnostic \/ companion diagnostic (CDx) use for solid tumor testing of tissue biopsies for NTRK fusion genes in cancer disease diagnosis and treatment selection.\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003e15 clinically-relevant NTRK fusion genes in a single reference sample\u003c\/li\u003e\n\u003cli\u003eOffered as purified RNA (spike-in mix) or FFPE for full process NGS assay validation and positive sample control\u003c\/li\u003e\n\u003cli\u003eFusions precisely quantitated with digital PCR\u003c\/li\u003e\n\u003cli\u003eWell-characterized GM24385 human genomic RNA as background wild-type material\u003c\/li\u003e\n\u003cli\u003eManufactured in GMP-compliant and ISO 13485-certified facility.\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eSpecifications\u003c\/h2\u003e\u003ctable\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e# of Variants\u003c\/td\u003e\n\u003ctd\u003e15\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eConcentration\u003c\/td\u003e\n\u003ctd\u003e25 ng\/µL\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFill Volume\u003c\/td\u003e\n\u003ctd\u003e20 µL\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal DNA\u003c\/td\u003e\n\u003ctd\u003e500 ng\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e# of Vials\u003c\/td\u003e\n\u003ctd\u003e1\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMatrix\u003c\/td\u003e\n\u003ctd\u003e1 mM Tris, pH 8.0\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e\u003ch2\u003eDocuments\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/ps-mkt-00538-01_seracare-seraseq_ntrk_fusion_rna_refmat.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq NTRK Fusion RNA Reference Materials (Product Sheet)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/pi-0710-1696-seraseq-ntrk-fusion-rna-mix.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq NTRK Fusion RNA Mix Product Insert (Package Insert)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/tss-0710-1031.1696-seraseq-ffpe-ntrk-fusion-rna-rm_technical-spreadsheet.xlsx\" target=\"_blank\" rel=\"noopener\"\u003eTechnical Spreadsheet for Seraseq NTRK Fusion RNA Reference Materials (Technical Spreadsheet)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/nrl-0710-1966-seraseq-ntrk.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq NTRK Fusion RNA Mix Non-Requirement Letter (SDS Non-Requirement Letter)\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eOrdering Information\u003c\/h2\u003e\u003ctable\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eCat. no.\u003c\/th\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eSize\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\u003ctr\u003e\n\u003ctd\u003e0710-1696\u003c\/td\u003e\n\u003ctd\u003eSeraseq® NTRK Fusion RNA Mix\u003c\/td\u003e\n\u003ctd\u003e1 x 20 µL\u003c\/td\u003e\n\u003c\/tr\u003e\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"SeraCare","offers":[{"title":"Default Title","offer_id":46798511439951,"sku":"0710-1696","price":0.0,"currency_code":"ILS","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0712\/0748\/5519\/files\/0710-1696.jpg?v=1789655848"},{"product_id":"seracare-seraseq-compromised-ffpe-wt-dna-rna-reference-material-0710-1710","title":"Seraseq® Compromised FFPE WT (DNA\/RNA) Reference Material","description":"\u003cp\u003eMolecular assays that profile tumor mutations in solid tissue biopsies require an efficient and precise evaluation of the pre-analytic portion of their workflow prior to downstream analysis by NGS or other methods. Contrived reference material or cell line-based standard can provide a critical input in the optimization of nucleic acid extraction from very challenging FFPE tissue materials without wasting precious mutation-positive tissue samples.\u003c\/p\u003e\u003cp\u003eWe have designed this FFPE cell line-based reference sample as a negative control to support the determination of assay specificity at wildtype base positions, as well as specificity at positions affected by mutations included in all of the Seraseq RNA and DNA (Mutation Mix and Reference Material) products.\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eCell line-based negative sample control (WT)\u003c\/li\u003e\n\u003cli\u003eComplementary assay control for all Seraseq DNA and RNA tumor reference materials\u003c\/li\u003e\n\u003cli\u003eOffered as light and moderate formalin-damaged FFPE for full process NGS assay workflow optimization\u003c\/li\u003e\n\u003cli\u003eWell-characterized GM24385 wild-type material\u003c\/li\u003e\n\u003cli\u003eManufactured in GMP-compliant and ISO 13485-certified facility.\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eSpecifications\u003c\/h2\u003e\u003ctable\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e# of Variants\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSize\u003c\/td\u003e\n\u003ctd\u003e10 µm\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDNA yield\u003c\/td\u003e\n\u003ctd\u003e205 ng\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRNA yield\u003c\/td\u003e\n\u003ctd\u003e1,1165 ng\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e# of Vials\u003c\/td\u003e\n\u003ctd\u003e1\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMatrix\u003c\/td\u003e\n\u003ctd\u003eFFPE\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e\u003ch2\u003eDocuments\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/ps-mkt-00525_seraseq-total-nucleic-acid-reference-materials.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq Total Nucleic Acid (Product Sheet)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/pi-0710-1710-seraseq-compromised-ffpe-wt-dna-rna-ref-material.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq Compromised FFPE WT (DNA\/RNA) Reference Material (Package Insert)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/sds-seraseq-ffpe.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq FFPE Safety Data Sheet (Safety Data Sheet)\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eOrdering Information\u003c\/h2\u003e\u003ctable\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eCat. no.\u003c\/th\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eSize\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\u003ctr\u003e\n\u003ctd\u003e0710-1710\u003c\/td\u003e\n\u003ctd\u003eSeraseq® Compromised FFPE WT (DNA\/RNA) RM\u003c\/td\u003e\n\u003ctd\u003e1 x 10 µm\u003c\/td\u003e\n\u003c\/tr\u003e\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"SeraCare","offers":[{"title":"Default Title","offer_id":46798511538255,"sku":"0710-1710","price":0.0,"currency_code":"ILS","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0712\/0748\/5519\/files\/0710-1710.jpg?v=1789655854"},{"product_id":"seracare-seraseq-blood-tmb-mix-0710-2087","title":"Seraseq® Blood TMB Mix","description":"\u003cp\u003eINTRODUCTION\u003c\/p\u003e\u003cp\u003eIn immuno-oncology, the goal is to enable a patient’s immune system to locate and eliminate cancerous cells. The immune system may normally protect against cancer – except when cancers manage to evade it – since immunocompromised individuals have a higher likelihood of developing cancer. Checkpoint inhibitors, which have recently improved the prognosis for a significant number of cancer patients, work by blocking inhibitory molecules such as PD-L1 and CTLA-4 that may be allowing cancers to evade the adaptive immune system. However, by taking the brakes off the immune system, the use of checkpoint inhibitors is associated with a significant risk of developing autoimmune disease. Additionally, frequently checkpoint inhibitors are not effective.\u003c\/p\u003e\u003cp\u003eIn order to maximize the safety and efficacy of checkpoint inhibitors, it is beneficial to identify patients who are likely to respond to their use. Since the adaptive immune system can detect changes to proteins, it is thought that the number of somatic mutations that lead to such changes may be correlated with efficacy. The metric of non-silent somatic mutations per megabase of coding DNA has been termed tumor mutational burden (TMB), which has shown some correlation to the efficacy of checkpoint inhibitors. Assessments of TMB are being added to many NGS assays to enable their use for patient selection in I-O clinical trials, and perhaps as companion diagnostics to these therapies. However, it is also known that TMB scores can differ significantly between assays and especially around levels that may be clinical decision points.\u003c\/p\u003e\u003cp\u003eTo improve and harmonize the measurement of TMB, we have generated and characterized tumor-normal human cell lines, fragmented and sized to ctDNA fragment sizes, and determined their Blood TMB scores by a targeted NGS panel.\u003c\/p\u003e\u003cp\u003eThe Blood TMB reference materials are formatted as ctDNA (purified mix) in three different tumor fractions.\u003c\/p\u003e\u003cp\u003eBlood TMB Reference Standards\u003cbr\u003eReference standards are made from human lung cancer cell lines and their SNP-matched normal cell lines from peripheral blood of the same patients.\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eFragmented and blended at 0%, 0.5% and 2% tumor fractions\u003c\/li\u003e\n\u003cli\u003eAvailable as a purified ctDNA mix, and ready as input into WES or targeted NGS library preparation\u003c\/li\u003e\n\u003cli\u003eBlood TMB scores determined using a targeted NGS panel (TSO500 plasma)\u003c\/li\u003e\n\u003cli\u003eManufactured in GMP-compliant and ISO 13485 certified facilities\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eSpecifications\u003c\/h2\u003e\u003ctable\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTumor Fractions\u003c\/td\u003e\n\u003ctd\u003e0%, 0.5%, 2%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFill Volume\u003c\/td\u003e\n\u003ctd\u003e20 µL\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eConcentration\u003c\/td\u003e\n\u003ctd\u003e10 ng\/µl\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Mass\u003c\/td\u003e\n\u003ctd\u003e3 x 200 ng\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e\u003ch2\u003eDocuments\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/PS-MKT-00504-04-0710-1326.0710-1325.0710-1586.0710-1324.0710-1323.0710-2087.0710-2088.0710-2089.0710-2090.0710-1310.0710-1308.0710-1618.0710-1309.0710-1307.Seraseq_gDNA_ctDNA_and_FFPE_TMB_Products.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq gDNA, ctDNA and FFPE TMB Product Sheet (Product Sheet)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/ds-mkt-00615-04_0710-20870710-20880710-20890710-2090_seraseq_blood_tmb-mix.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq® Blood TMB Mix Datasheet Score 7, 13, 20, 26 (Data Sheet)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/pi-0710-2087.2090-seraseq-blood-tmb.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq Blood TMB Mix Score 7, 13, 20 \u0026amp; 26 (Package Insert)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/nrl-0710-2087-2090-seraseq-blood-tmb.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq Blood TMB Mix Non-Requirement Letter (SDS Non-Requirement Letter)\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eOrdering Information\u003c\/h2\u003e\u003ctable\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eCat. no.\u003c\/th\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eSize\u003c\/th\u003e\n\u003cth\u003eBlood TMB Score\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e0710-2087\u003c\/td\u003e\n\u003ctd\u003eSeraseq® Blood TMB Mix Score 7\u003c\/td\u003e\n\u003ctd\u003e3 x 20 µL\u003c\/td\u003e\n\u003ctd\u003e5.6 ± 2.1 (0.5% TF) 10.4 ± 1.7 (2% TF)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e0710-2088\u003c\/td\u003e\n\u003ctd\u003eSeraseq® Blood TMB Mix Score 13\u003c\/td\u003e\n\u003ctd\u003e3 x 20 µL\u003c\/td\u003e\n\u003ctd\u003e14.1 - 20.0\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e0710-2089\u003c\/td\u003e\n\u003ctd\u003eSeraseq® Blood TMB Mix Score 20\u003c\/td\u003e\n\u003ctd\u003e3 x 20 µL\u003c\/td\u003e\n\u003ctd\u003e18.5 - 28.1\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e0710-2090\u003c\/td\u003e\n\u003ctd\u003eSeraseq® Blood TMB Mix Score 26\u003c\/td\u003e\n\u003ctd\u003e3 x 20 µL\u003c\/td\u003e\n\u003ctd\u003e14.7 ± 2.4 (0.5% TF) 24.4 ± 1.5 (2% TF)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"SeraCare","offers":[{"title":"Score 7","offer_id":46798511571023,"sku":"0710-2087","price":0.0,"currency_code":"ILS","in_stock":true},{"title":"Score 13","offer_id":46798511603791,"sku":"0710-2088","price":0.0,"currency_code":"ILS","in_stock":true},{"title":"Score 20","offer_id":46798511636559,"sku":"0710-2089","price":0.0,"currency_code":"ILS","in_stock":true},{"title":"Score 26","offer_id":46798511669327,"sku":"0710-2090","price":0.0,"currency_code":"ILS","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0712\/0748\/5519\/files\/0710-2087.jpg?v=1789655854"},{"product_id":"seracare-seraseq-ctdna-mrd-panel-mix-0710-2146","title":"Seraseq® ctDNA MRD Panel Mix","description":"\u003cp\u003eINTRODUCTION\u003c\/p\u003e\u003cp\u003eMRD monitoring typically involves measuring signs of a cancer in order to determine if it is disappearing (progression) or returning (relapse). Typically, this can be facilitated by use of less invasive techniques such as liquid biopsy (ctDNA), to monitor cancer-specific somatic variants. A patient-derived approach to the application of ctDNA-based MRD monitoring starts with a tumor profiling analysis to identify clinically relevant tumor variants that constitute the patient’s genomic profile. Following this, a targeted panel\/assay containing a subset of the gene variants can be designed for disease monitoring by detecting presence or absence of circulating tumor (ct)DNA variants in the patient’s blood sample. These patient-derived MRD analyses represent a paradigm shift in disease monitoring, and have been adopted by leading liquid biopsy NGS vendors such as Natera’s Signatera® platform and Archer\/Invitae’s Personalized Cancer Monitoring (PCM) assay.\u003c\/p\u003e\u003cp\u003eLGC SeraCare has developed a novel ctDNA MRD mutation mix panel designed to support the development, validation and clinical deployment of ctDNA-based patient-derived MRD monitoring NGS assays. The new Seraseq ctDNA MRD Panel Mix product is constructed from combination of a diseased human cell line, its SNP-matched normal cell line, and biosynthetic DNA containing variants commonly targeted by therapeutic drugs (see list below). The blended DNA is fragmented, sized to mimic ctDNA fragment sizes, and serially diluted to tumor fractions (TF) of 0%, 0.5%, 0.05% and 0.005%.\u003c\/p\u003e\u003cp\u003eFEATURES AND BENEFITS\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eCombination of diseased human cancer cell line, its SNP-matched normal and biosynthetic DNA variants.\u003c\/li\u003e\n\u003cli\u003eFragmented, sized (ctDNA), and blended at four tumor levels: 0% (WT), 0.5%, 0.05% and 0.005%.\u003c\/li\u003e\n\u003cli\u003eDevelop, validate and routinely determine presence\/absence of patient-derived disease variants with high precision (against a matched normal (WT) background).\u003c\/li\u003e\n\u003cli\u003eVariant detection and VAF analysis by digital PCR and targeted cfDNA NGS assay.\u003c\/li\u003e\n\u003cli\u003eAvailable as a purified DNA mix ready for targeted sequencing library prep.\u003c\/li\u003e\n\u003cli\u003eManufactured in GMP-compliant and ISO 13485-certified facilities.\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eSpecifications\u003c\/h2\u003e\u003ctable\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e# of Variants\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;600\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTumor Levels\u003c\/td\u003e\n\u003ctd\u003e0%, 0.5%, 0.05% \u0026amp; 0.005%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e# of Vials\u003c\/td\u003e\n\u003ctd\u003e4\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFill Volume\u003c\/td\u003e\n\u003ctd\u003e20 µ l\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eConcentration\u003c\/td\u003e\n\u003ctd\u003e10 ng\/µl\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Mass\u003c\/td\u003e\n\u003ctd\u003e4 x 200 ng\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFormat\u003c\/td\u003e\n\u003ctd\u003ePurified DNA in buffer (Tris\/EDTA)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e\u003ch2\u003eDocuments\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/ps-0710-2146-mkt-00617-seraseq-ctdna-mrd-panel-mix.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq® ctDNA MRD Mix (Product Sheet)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/ds-mkt-00626-0710-2146-seraseq-ctdna-mrd-panel-mix.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq ctDNA MRD Panel Mix - Datasheet (Data Sheet)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/pi-0710-2146-seraseq-ctdna-mrd-panel-mix.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq ctDNA MRD Mix - Package Insert (Package Insert)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/nrl-0710-2146-seraseq-gdna-mrd-mix.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq ctDNA MRD Panel Mix Non-Requirement Letter (SDS Non-Requirement Letter)\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eOrdering Information\u003c\/h2\u003e\u003ctable\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eCat. no.\u003c\/th\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eSize\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\u003ctr\u003e\n\u003ctd\u003e0710-2146\u003c\/td\u003e\n\u003ctd\u003eSeraseq® ctDNA MRD Panel Mix\u003c\/td\u003e\n\u003ctd\u003e4 x 20 µL\u003c\/td\u003e\n\u003c\/tr\u003e\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"SeraCare","offers":[{"title":"Default Title","offer_id":46798511833167,"sku":"0710-2146","price":0.0,"currency_code":"ILS","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0712\/0748\/5519\/files\/0710-2146.jpg?v=1789655861"},{"product_id":"seracare-seraseq-whole-transcriptome-rna-seq-mix-0710-2129","title":"Seraseq® Whole Transcriptome RNA Seq Mix","description":"\u003cp\u003e\u003cstrong\u003eINTRODUCTION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eWhole transcriptome RNA sequencing allows for the analysis of fusion genes with potential clinical utility that currently cannot be detected using the limited genomic coverage of targeted NGS panels. Additionally, some clinical cancer testing labs are evaluating whole transcriptome panels for improved diagnostic yields and clinical utilization for NGS-based tumor profiling test reimbursements. Expanding fusion gene content and higher detection efficiencies will expand use of fusion analysis in clinical NGS applications. Maybe most importantly is that new therapies are targeting fusion genes as clinical biomarkers for treatments of various adult and pediatric cancers.\u003c\/p\u003e\n\u003cp\u003eSeraCare has developed a novel whole transcriptome RNA sequencing reference material for analysis of 22 fusion genes with clinical applications in oncology as analyzed by a whole transcriptome NGS assay. Such assays provide a comprehensive view of the transcriptome with ability to detect known and novel fusions of clinical utility. This reference material is offered as a purified RNA mix with high titer concentration for all 22 RNA fusion constructs.\u003c\/p\u003e\n\u003cp\u003eFEATURES AND BENEFITS\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eSingle sample with 22 clinically-relevant RNA gene fusions.\u003c\/li\u003e\n\u003cli\u003ePurified RNA format ready for total RNA transcriptome sequencing library prep.\u003c\/li\u003e\n\u003cli\u003eFusion copies accurately quantitated using digital PCR.\u003c\/li\u003e\n\u003cli\u003eFusion constructs blended into total RNA from well-characterized GM24385 cell line as wild-type background.\u003c\/li\u003e\n\u003cli\u003eManufactured in GMP-compliant and ISO 13485-certified facilities.\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eSpecifications\u003c\/h2\u003e\u003ctable\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e# of Fusions\u003c\/td\u003e\n\u003ctd\u003e22\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eConcentration\u003c\/td\u003e\n\u003ctd\u003e50 ng\/µl\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFill Volume\u003c\/td\u003e\n\u003ctd\u003e20 µL\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Mass\u003c\/td\u003e\n\u003ctd\u003e1 ug\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFormat\u003c\/td\u003e\n\u003ctd\u003ePurified RNA\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBuffer\u003c\/td\u003e\n\u003ctd\u003e1mM Tris; pH 8\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e\u003ch2\u003eDocuments\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/ps---mkt-00616--02-seraseq-whole-transcriptome-rna-seq-mix.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq Whole Transcriptome RNA Seq Mix - Product Sheet (Product Sheet)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/pi-0710-2129-seraseq-whole-transcriptome-rna-seq-mix.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq Whole Transcriptome RNA Seq Mix Product Insert (Package Insert)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/tss-0710-2129-technical-spreadsheet-for-seraseq-whole-transcriptome-rna-seq-mix.xlsx\" target=\"_blank\" rel=\"noopener\"\u003eTechnical Spreadsheet for Seraseq Whole Transcriptome RNA-Seq Mix (Technical Spreadsheet)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/nrl-0710-2129-seraseq-whole-transcriptome.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq Whole Transcriptome RNA Seq Mix Non-Requirement Letter (SDS Non-Requirement Letter)\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eOrdering Information\u003c\/h2\u003e\u003ctable\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eCat. no.\u003c\/th\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eSize\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\u003ctr\u003e\n\u003ctd\u003e0710-2129\u003c\/td\u003e\n\u003ctd\u003eSeraseq® Whole Transcriptome RNA Seq Mix\u003c\/td\u003e\n\u003ctd\u003e1 x 20 µL\u003c\/td\u003e\n\u003c\/tr\u003e\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"SeraCare","offers":[{"title":"Default Title","offer_id":46798511767631,"sku":"0710-2129","price":0.0,"currency_code":"ILS","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0712\/0748\/5519\/files\/0710-2129.jpg?v=1789655861"},{"product_id":"seracare-seraseq-ffpe-lymphoma-dna-reference-material-0710-2202","title":"Seraseq® FFPE Lymphoma DNA Reference Material","description":"\u003cp\u003e\u003cstrong\u003eINTRODUCTION\u003c\/strong\u003e\u003c\/p\u003e\u003cp\u003eTo help clinical labs performing NGS-based lymphoid testing better develop, characterize, validate and routinely assess lymphoid diseases by NGS assays, LGC SeraCare has developed the Seraseq Lymphoma DNA Mutation Mix and Seraseq FFPE Lymphoma Reference Material, the first set of comprehensive lymphoid cancer NGS assay reference materials. These unique products include clinically important SNVs, INDELs and gene fusions important in lymphoma disease diagnosis and prognosis. Variants are present against a single well-characterized genomic background (GM24385) at clinically relevant allele frequencies, precisely quantitated by digital PCR assays.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eFEATURES AND BENEFITS\u003c\/strong\u003e\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eDevelop and validate Lymphoid-based NGS assays with confidence using a highly multiplexed reference material containing biomarkers important in Lymphoma cancers.\u003c\/li\u003e\n\u003cli\u003eProvide robust sensitivity to detect clinically-relevant mutations at variant allele frequencies that establish and validate assay LoD claims.\u003c\/li\u003e\n\u003cli\u003eMutation targets are quantitated using highly sensitive digital PCR as well as a custom NGS assay.\u003c\/li\u003e\n\u003cli\u003eAll mutations are blended against GM24385 human genomic DNA as background ‘wild-type’ material.\u003c\/li\u003e\n\u003cli\u003eAvailable as both purified DNA mix and FFPE curls, for end-to-end assay workflow positive control.\u003c\/li\u003e\n\u003cli\u003eManufactured in GMP-compliant and ISO 13485-certified facilities.\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eSpecifications\u003c\/h2\u003e\u003ctable\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e# of Variants\u003c\/td\u003e\n\u003ctd\u003e26\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e# of Vials\u003c\/td\u003e\n\u003ctd\u003e1\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFill Volume\u003c\/td\u003e\n\u003ctd\u003e10 µm\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eConcentration\u003c\/td\u003e\n\u003ctd\u003e1 FFPE curl\/vial\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Mass\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;100 ng*\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFormat\u003c\/td\u003e\n\u003ctd\u003eFFPE\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e\u003ch2\u003eDocuments\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/ps-mkt-00631-0710-2202.2203-seraseq-lymphoma-dna.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq Lymphoma DNA - Product Sheet (Product Sheet)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/pi-0710-2202-seraseq-lymphoma-dna.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq FFPE Lymphoma DNA Reference Material (Package Insert)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/tss-0710-2202.2203-seraseq-ffpe-lymphoma-dna-reference-material.xlsx\" target=\"_blank\" rel=\"noopener\"\u003eTechnical Spreadsheet for Seraseq Lymphoma FFPE Reference Material and DNA Mutation Mix (Technical Spreadsheet)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/sds-seraseq-ffpe.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq FFPE Safety Data Sheet (Safety Data Sheet)\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eOrdering Information\u003c\/h2\u003e\u003ctable\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eCat. no.\u003c\/th\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eSize\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\u003ctr\u003e\n\u003ctd\u003e0710-2202\u003c\/td\u003e\n\u003ctd\u003eSeraseq® FFPE Lymphoma DNA Reference Material\u003c\/td\u003e\n\u003ctd\u003e1 x 10 µm\u003c\/td\u003e\n\u003c\/tr\u003e\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"SeraCare","offers":[{"title":"Default Title","offer_id":46798511865935,"sku":"0710-2202","price":0.0,"currency_code":"ILS","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0712\/0748\/5519\/files\/0710-2202.jpg?v=1789655868"},{"product_id":"seracare-seraseq-lymphoma-dna-mutation-mix-0710-2203","title":"Seraseq® Lymphoma DNA Mutation Mix","description":"\u003cp\u003e\u003cstrong\u003eINTRODUCTION\u003c\/strong\u003e\u003c\/p\u003e\u003cp\u003eTo help clinical labs performing NGS-based lymphoid testing better develop, characterize, validate and routinely assess lymphoid diseases by NGS assays, LGC SeraCare has developed the Seraseq Lymphoma DNA Mutation Mix and Seraseq FFPE Lymphoma Reference Material, the first set of comprehensive lymphoid cancer NGS assay reference materials. These unique products include clinically important SNVs, INDELs and gene fusions important in lymphoma disease diagnosis and prognosis. Variants are present against a single well-characterized genomic background (GM24385) at clinically relevant allele frequencies, precisely quantitated by digital PCR assays.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eFEATURES AND BENEFITS\u003c\/strong\u003e\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eDevelop and validate Lymphoid-based NGS assays with confidence using a highly multiplexed reference material containing biomarkers important in Lymphoma cancers.\u003c\/li\u003e\n\u003cli\u003eProvide robust sensitivity to detect clinically-relevant mutations at variant allele frequencies that establish and validate assay LoD claims.\u003c\/li\u003e\n\u003cli\u003eMutation targets are quantitated using highly sensitive digital PCR as well as a custom NGS assay.\u003c\/li\u003e\n\u003cli\u003eAll mutations are blended against GM24385 human genomic DNA as background ‘wild-type’ material.\u003c\/li\u003e\n\u003cli\u003eAvailable as both purified DNA mix and FFPE curls, for end-to-end assay workflow positive control.\u003c\/li\u003e\n\u003cli\u003eManufactured in GMP-compliant and ISO 13485-certified facilities.\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eSpecifications\u003c\/h2\u003e\u003ctable\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e# of Variants\u003c\/td\u003e\n\u003ctd\u003e26\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e# of Vials\u003c\/td\u003e\n\u003ctd\u003e1\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFill Volume\u003c\/td\u003e\n\u003ctd\u003e25 µL\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eConcentration\u003c\/td\u003e\n\u003ctd\u003e15 ng\/µl\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Mass\u003c\/td\u003e\n\u003ctd\u003e375 ng\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFormat\u003c\/td\u003e\n\u003ctd\u003ePurified DNA in Buffer (Tris\/EDTA)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e\u003ch2\u003eDocuments\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/ps-mkt-00631-0710-2202.2203-seraseq-lymphoma-dna.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq Lymphoma DNA - Product Sheet (Product Sheet)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/pi-0710-2203-seraseq-lymphoma-dna-mm.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq Lymphoma DNA - Package Insert Mutation Mix - Package Insert (Package Insert)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/tss-0710-2202.2203-seraseq-ffpe-lymphoma-dna-reference-material.xlsx\" target=\"_blank\" rel=\"noopener\"\u003eTechnical Spreadsheet for Seraseq Lymphoma FFPE Reference Material and DNA Mutation Mix (Technical Spreadsheet)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/nrl-0710-2203-seraseq-lymphoma-dna.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq Lymphoma DNA Non-Requirement Letter (SDS Non-Requirement Letter)\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eOrdering Information\u003c\/h2\u003e\u003ctable\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eCat. no.\u003c\/th\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eSize\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\u003ctr\u003e\n\u003ctd\u003e0710-2203\u003c\/td\u003e\n\u003ctd\u003eSeraseq® Lymphoma DNA Mutation Mix\u003c\/td\u003e\n\u003ctd\u003e1 x 25 µL\u003c\/td\u003e\n\u003c\/tr\u003e\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"SeraCare","offers":[{"title":"Default Title","offer_id":46798511964239,"sku":"0710-2203","price":0.0,"currency_code":"ILS","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0712\/0748\/5519\/files\/0710-2203.jpg?v=1789655875"},{"product_id":"seracare-seraseq-ffpe-msi-high-reference-material-0710-2236","title":"Seraseq® FFPE MSI-High Reference Material","description":"\u003cp\u003eINTRODUCTION\u003c\/p\u003e\u003cp\u003eMicrosatellites are regions of DNA repeats with different lengths, i.e., instability, highlighting DNA mismatch repair gene deficiencies. Typical repeat units are between 1-6 base pairs and the number of repeats vary from person to person such that each person has a set length of these microsatellites in their genome. Measurements of MSI have traditionally been performed using qPCR\/CE fragment length analysis methods, or immunohistochemistry (IHC), but new methodologies such as digital droplet PCR (ddPCR) and Next Generation Sequencing (NGS) are now being applied to determination of MSI status of cancer patients. High incidence of microsatellite instability (MSI) has been linked to favorable outcomes in immuno-oncology (I-O) treatment response by patients with diseases such as Lynch Syndrome and colorectal cancer. Hence determination of MSI status for cancer patients is important in I-O therapeutics management.\u003c\/p\u003e\u003cp\u003eLGC SeraCare has developed microsatellite instability (MSI) reference materials that support qPCR and NGS assays that target a range of short tandem repeat regions commonly analyzed for microsatellite instabilities. For assays that target specific mono and dinucleotide repeats such as BAT-25, BAT-26, NR-21, NR-24, MONO-27, we have created MSI reference materials containing these markers blended at two different allele frequency (AF) levels – 5% and 20%. Additionally, for NGS MSI assays that analyze for a large number of microsatellite loci across the human genome, we have a human diseased cell line-based MSI-High reference material for such analysis. These products are quantitated by PCR (qPCR\/CE and ddPCR) and by targeted NGS assays to support all product claims.\u003c\/p\u003e\u003cp\u003eFEATURES AND BENEFITS\u003cbr\u003e• Cell line or plasmid-based MSI reference material mix for analysis in molecular assays or NGS\u003cbr\u003e• Offered as tumor-only (MSI-High) or tumor-normal (AF5% and AF20%) options\u003cbr\u003e• Support MSI assay validation, LoD determination, and routine detection of MSI markers in cancer patient samples \u003cbr\u003e• Variant AFs (AF5% and AF20% products) quantitated by ddPCR and qPCR\/CE fragment length analysis assays\u003cbr\u003e• Normal background DNA is a highly characterized GM24385 human genomic DNA known to be microsatellite stable (MSS) \u003cbr\u003e• Manufactured within cGMP compliant and ISO 13485 certified facilities\u003c\/p\u003e\u003ch2\u003eSpecifications\u003c\/h2\u003e\u003ctable\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e# of Variants\u003c\/td\u003e\n\u003ctd\u003eVariable\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAllele Frequency\u003c\/td\u003e\n\u003ctd\u003eVariable\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eConcentration\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFill Volume\u003c\/td\u003e\n\u003ctd\u003e10 µm\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal DNA\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;200 ng\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e# of Vials\u003c\/td\u003e\n\u003ctd\u003e1 (tumor only)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMatrix\u003c\/td\u003e\n\u003ctd\u003eFFPE\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e\u003ch2\u003eDocuments\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/ps-mkt-00534_0710-1670.0710-2236.0710-1675.0710-1676_seraseq_msi-reference_materials.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq MSI Reference Materials Product Sheet (Product Sheet)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/pi-0710-2236-seraseq-ffpe-msi-high-reference-material.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq FFPE MSI-High Reference Material (Package Insert)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/sds-seraseq-ffpe.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq FFPE Safety Data Sheet (Safety Data Sheet)\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eOrdering Information\u003c\/h2\u003e\u003ctable\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eCat. no.\u003c\/th\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eSize\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\u003ctr\u003e\n\u003ctd\u003e0710-2236\u003c\/td\u003e\n\u003ctd\u003eSeraseq® FFPE MSI-High RM\u003c\/td\u003e\n\u003ctd\u003e1 x 10 µm\u003c\/td\u003e\n\u003c\/tr\u003e\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"SeraCare","offers":[{"title":"Default Title","offer_id":46798511997007,"sku":"0710-2236","price":0.0,"currency_code":"ILS","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0712\/0748\/5519\/files\/0710-2236.jpg?v=1789655875"},{"product_id":"seracare-seraseq-gdna-tmb-reference-panel-mix-0710-2463","title":"Seraseq® gDNA TMB Reference Panel Mix","description":"\u003cp\u003eThe level of somatic mutations in a tumor, called tumor mutational burden (TMB), is used as a biomarker to predict patient response to immune checkpoint inhibitor therapy, with cancer type-specific TMB cut-offs of clinical value. Whole exome sequencing (WES) has been the gold standard to measure TMB. While targeted panels have the capacity to estimate TMB, TMB scores can vary significantly depending on the panel size, coverage regions, and bioinformatics pipeline used to make variant calls. LGC SeraCare has developed Seraseq gDNA TMB Reference Panel Mix, which has been extensively validated using WES and can be used to guide TMB score assessment using targeted panels, especially around values that may be clinical decision points for different tumor types. Each Seraseq gDNA TMB Reference Panel Mix contains five vials of purified genomic DNA from tumor-like human cell lines encompassing complex genomic signatures over a broad range of TMB scores, all in one kit.\u003c\/p\u003e\u003ch2\u003eDocuments\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/ps-0710-2463_seraseq_gdna_tmb_reference_panel_mix.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq gDNA TMB Reference Panel Mix Product Sheet (Product Sheet)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/ds-0710-2463-seraseq-gdna-tmb-rerefence-panel-mix.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq gDNA TMB Reference Panel Mix (Data Sheet)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/pi-0710-2463-seraseq-gdna-tmb-reference-panel-mix.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq gDNA TMB Reference Panel Mix Package Insert (Package Insert)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/nrl-0710-2463.1326.1325-seraseq-gdna-tmb.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq gDNA TMB Non-Requirement Letter (SDS Non-Requirement Letter)\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eOrdering Information\u003c\/h2\u003e\u003ctable\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eCat. no.\u003c\/th\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eSize\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\u003ctr\u003e\n\u003ctd\u003e0710-2463\u003c\/td\u003e\n\u003ctd\u003eSeraseq® gDNA TMB Reference Panel Mix\u003c\/td\u003e\n\u003ctd\u003e5 x 20 µL\u003c\/td\u003e\n\u003c\/tr\u003e\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"SeraCare","offers":[{"title":"Default Title","offer_id":46798512062543,"sku":"0710-2463","price":0.0,"currency_code":"ILS","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0712\/0748\/5519\/files\/0710-2463.jpg?v=1789655881"},{"product_id":"seracare-seraseq-myeloid-ctdna-mix-0710-2649","title":"Seraseq® Myeloid ctDNA Mix","description":"\u003cp\u003eTo help clinical labs performing NGS-based myeloid testing characterize the limit of detection (LOD) of their liquid biopsy assays and validate robust sensitivity, SeraCare has developed myeloid cancer NGS reference material in ctDNA format to ensure compatibility with existing and emerging myeloid assays. \u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eSingle sample with 25 clinically relevant DNA variants across 17 genes \u003c\/li\u003e\n\u003cli\u003eExpert-designed to ensure coverage across important variants (mix of SNVs, INDELs, and ITD) at relevant allele frequencies (1%, 0.5%, 0.1%, WT) \u003c\/li\u003e\n\u003cli\u003eBuilt with innovative technology to produce patient-like sample performance in NGS assays \u003c\/li\u003e\n\u003cli\u003eVariants precisely quantified using highly sensitive digital PCR assays, and blended with a single well-characterized genomic background (GM24385) \u003c\/li\u003e\n\u003cli\u003eValidated by targeted NGS panels \u003c\/li\u003e\n\u003cli\u003eManufactured in GMP-compliant, ISO 13485-certified facilities\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eSpecifications\u003c\/h2\u003e\u003ctable\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e# of Variants\u003c\/td\u003e\n\u003ctd\u003e25\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eConcentrations\u003c\/td\u003e\n\u003ctd\u003e15 ng\/µL\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAmount\u003c\/td\u003e\n\u003ctd\u003e375 ng (single vial)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBuffer\u003c\/td\u003e\n\u003ctd\u003e1 mM Tris, 0.1 mM EDTA, 10 mM KCl, pH 8.0\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e\u003ch2\u003eDocuments\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/ps-0710-2646.2647.2648.2649.0407.0408-seraseq-myeloid-rm.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq Myeloid Reference Materials: DNA, RNA Fusion, ctDNA Product Sheet (Product Sheet)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/pi-0710-2646-2649-seraseq-ctdna-myeloid-mix.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq ctDNA Myeloid Mix AF1%, AF0.5%, AF0.1%, WT (Package Insert)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/tss-0710-2646.2647.2648.2549-seraseq-myeloid-ctdna-mix.xlsx\" target=\"_blank\" rel=\"noopener\"\u003eTechnical Spreadsheet for Seraseq Myeloid ctDNA Mixes (Technical Spreadsheet)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/nrl-0710-2646-2649-seraseq-myeloid-ctdna-mix.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq ctDNA Myeloid Mix Non-Requirement Letter (SDS Non-Requirement Letter)\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eOrdering Information\u003c\/h2\u003e\u003ctable\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eCat. no.\u003c\/th\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eSize\u003c\/th\u003e\n\u003cth\u003eAllele Frequency\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e0710-2649\u003c\/td\u003e\n\u003ctd\u003eSeraseq Myeloid ctDNA Mix AF1%\u003c\/td\u003e\n\u003ctd\u003e1 x 25 µL\u003c\/td\u003e\n\u003ctd\u003e1%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e0710-2648\u003c\/td\u003e\n\u003ctd\u003eSeraseq Myeloid ctDNA Mix AF0.5%\u003c\/td\u003e\n\u003ctd\u003e1 x 25 µL\u003c\/td\u003e\n\u003ctd\u003e0.5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e0710-2647\u003c\/td\u003e\n\u003ctd\u003eSeraseq Myeloid ctDNA Mix AF0.1%\u003c\/td\u003e\n\u003ctd\u003e1 x 25 µL\u003c\/td\u003e\n\u003ctd\u003e0.1%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e0710-2646\u003c\/td\u003e\n\u003ctd\u003eSeraseq Myeloid ctDNA Mix WT\u003c\/td\u003e\n\u003ctd\u003e1 x 25 µL\u003c\/td\u003e\n\u003ctd\u003e0% (WT)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"SeraCare","offers":[{"title":"AF1%","offer_id":46798512160847,"sku":"0710-2649","price":0.0,"currency_code":"ILS","in_stock":true},{"title":"AF0.5%","offer_id":46798512193615,"sku":"0710-2648","price":0.0,"currency_code":"ILS","in_stock":true},{"title":"AF0.1%","offer_id":46798512226383,"sku":"0710-2647","price":0.0,"currency_code":"ILS","in_stock":true},{"title":"WT","offer_id":46798512259151,"sku":"0710-2646","price":0.0,"currency_code":"ILS","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0712\/0748\/5519\/files\/0710-2649.jpg?v=1789655886"},{"product_id":"seracare-seraseq-ffpe-hrd-reference-material-0710-2643","title":"Seraseq® FFPE HRD Reference Material","description":"\u003cp\u003eGenomic instability resulting from homologous recombination DNA repair deficiency (HRD) is a response biomarker to assess ovarian and breast cancer patient eligibility for PARP inhibitor and platinum-based therapies. HRD measurements have the potential to improve cancer therapy, however standardizing and democratizing HRD measurements remains challenging. LGC SeraCare has developed HRD reference materials to support the development, validation, and routine determination of HRD status in cancer patients.\u003c\/p\u003e\u003cp\u003e\u003c\/p\u003e\u003cp\u003e• Derived from tumor and matched-normal human cell lines\u003c\/p\u003e\u003cp\u003e\u003c\/p\u003e\u003cp\u003e• Blended to ~65% tumor content with SNP-matched normal cell lines\u003c\/p\u003e\u003cp\u003e\u003c\/p\u003e\u003cp\u003e• Additional biosynthetic single-nucleotide variants (SNVs) of 4 homologous recombination repair (HRR) genes\u003c\/p\u003e\u003cp\u003e\u003c\/p\u003e\u003cp\u003e• 10 µm FFPE curl with DNA yield \u0026gt;100 ng per curl\u003c\/p\u003e\u003cp\u003e\u003c\/p\u003e\u003cp\u003e• Full-process FFPE format reference material validated by NGS and microarray assays with various HRD algorithms (see the Data Sheet for more details) \u003c\/p\u003e\u003cp\u003e\u003c\/p\u003e\u003cp\u003e• Manufactured in GMP-compliant, ISO 13485-certified facilities\u003c\/p\u003e\u003ch2\u003eDocuments\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/ps-0710-2643-2645-seraseq-ffpe-hrd-rm.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq FFPE HRD (High-Positive, Low-Positive, Negative) Reference Material Product Sheet (Product Sheet)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/ds-0710-2643-2645-seraseq-ffpe-hrd-rm.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq FFPE HRD (High-Positive, Low-Positive, Negative) Reference Material (Data Sheet)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/pi-0710-2643-2645-seraseq-ffpe-hrd-rm.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq FFPE HRD (High-Positive, Low-Positive, Negative) Reference Material Package Insert (Package Insert)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/tss-0710-2879.2880.2881-seraseq-gdna-hrd-mix.xlsx\" target=\"_blank\" rel=\"noopener\"\u003eTechnical Spreadsheet for Seraseq HRD Reference Materials (Technical Spreadsheet)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/sds-seraseq-ffpe.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq FFPE Safety Data Sheet (Safety Data Sheet)\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eOrdering Information\u003c\/h2\u003e\u003ctable\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eCat. no.\u003c\/th\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eSize\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e0710-2643\u003c\/td\u003e\n\u003ctd\u003eSeraseq® FFPE HRD High-Positive RM\u003c\/td\u003e\n\u003ctd\u003e1 x 10 µm\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e0710-2644\u003c\/td\u003e\n\u003ctd\u003eSeraseq® FFPE HRD Negative RM\u003c\/td\u003e\n\u003ctd\u003e1 x 10 µm\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e0710-2645\u003c\/td\u003e\n\u003ctd\u003eSeraseq® FFPE HRD Low-Positive RM\u003c\/td\u003e\n\u003ctd\u003e1 x 10 µm\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"SeraCare","offers":[{"title":"High-Positive","offer_id":46798512291919,"sku":"0710-2643","price":0.0,"currency_code":"ILS","in_stock":true},{"title":"Negative","offer_id":46798512324687,"sku":"0710-2644","price":0.0,"currency_code":"ILS","in_stock":true},{"title":"Low-Positive","offer_id":46798512357455,"sku":"0710-2645","price":0.0,"currency_code":"ILS","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0712\/0748\/5519\/files\/0710-2643.jpg?v=1789655887"},{"product_id":"seracare-seraseq-solid-tumor-cnv-mix-0710-2866","title":"Seraseq® Solid Tumor CNV Mix","description":"\u003cp\u003eGene amplifications and deletions, collectively called copy number variations (CNVs), are common in cancer cells and contribute to uncontrolled cell growth, drug sensitivity and resistance. To support clinical labs performing NGS-based tumor profiling of cancer patient samples and help assay developers develop and characterize the performance of their assays, LGCSeraCare has developed a comprehensive solid tumor CNV reference material in mutation mix format. \u003c\/p\u003e\u003cp\u003e\u003cb\u003eFEATURES AND BENEFITS\u003c\/b\u003e\u003c\/p\u003e \u003cul\u003e\n\u003cli\u003e12 clinically relevant CNVs associated with solid tumors\u003c\/li\u003e\n\u003cli\u003eA single reference material carrying gene amplifications at various levels\u003c\/li\u003e\n\u003cli\u003eCopy numbers quantified using sensitive dPCR assays and blended with the well-characterized GM24385 genomic background\u003c\/li\u003e\n\u003cli\u003eValidated by a targeted NGS panel\u003c\/li\u003e\n\u003cli\u003eManufactured in GMP-compliant, ISO 13485-certified facilities\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eDocuments\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/mkt-00929-rev-122.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq Solid Tumor CNV Mix 3 Copies (Product Sheet)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/mkt-00929-rev-12.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq® Solid Tumor CNV Mix, +6 copies (Product Sheet)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/mkt-00929-rev-13.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq Solid Tumor CNV Mix 12 Copies (Product Sheet)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/pi-0710.2866.2867.2868-seraseq-solid-tumor-cnv-mix.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq Solid Tumor CNV Mixes (Package Insert)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/pi-0710.2866.2867.2868-seraseq-solid-tumor-cnv-mix2.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq Solid Tumor CNV Mix Package Insert (Package Insert)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/ts-0710-2865-seraseq-ffpe-solid-tumor-cnv-rm.xlsx\" target=\"_blank\" rel=\"noopener\"\u003eTechnical Spreadsheet for Seraseq FFPE Solid Tumor CNV Reference Material and Seraseq Solid Tumor CNV Mixes (Technical Spreadsheet)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/nrl-0710-2866-2868-seraseq-solid-tumor.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq Solid Tumor Mixes Non-Requirement Letter (SDS Non-Requirement Letter)\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eOrdering Information\u003c\/h2\u003e\u003ctable\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eCat. no.\u003c\/th\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eSize\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e0710-2866\u003c\/td\u003e\n\u003ctd\u003eSeraseq® Solid Tumor CNV Mix, +3 copies\u003c\/td\u003e\n\u003ctd\u003e1 x 20 µL\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e0710-2867\u003c\/td\u003e\n\u003ctd\u003eSeraseq® Solid Tumor CNV Mix, +6 copies\u003c\/td\u003e\n\u003ctd\u003e1 x 20 µL\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e0710-2868\u003c\/td\u003e\n\u003ctd\u003eSeraseq® Solid Tumor CNV Mix, +12 copies\u003c\/td\u003e\n\u003ctd\u003e1 x 20 µL\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"SeraCare","offers":[{"title":"+3 copies","offer_id":46798512554063,"sku":"0710-2866","price":0.0,"currency_code":"ILS","in_stock":true},{"title":"+6 copies","offer_id":46798512586831,"sku":"0710-2867","price":0.0,"currency_code":"ILS","in_stock":true},{"title":"+12 copies","offer_id":46798512619599,"sku":"0710-2868","price":0.0,"currency_code":"ILS","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0712\/0748\/5519\/files\/0710-2866.jpg?v=1789655892"},{"product_id":"seracare-seraseq-ffpe-solid-tumor-cnv-reference-materials-0710-2865","title":"Seraseq® FFPE Solid Tumor CNV Reference Materials","description":"\u003cp\u003eGene amplifications and deletions, collectively called copy number variations (CNVs), are common in cancer cells and contribute to uncontrolled cell growth, drug sensitivity and resistance. To support clinical labs performing NGS-based tumor profiling of cancer patient samples and help assay developers develop and characterize the performance of their assays, LGCSeraCare has developed a comprehensive solid tumor CNV reference material in formalin-fixed paraffin-embedded (FFPE) format.\u003c\/p\u003e\u003cp\u003e\u003cb\u003eFEATURES AND BENEFITS\u003c\/b\u003e\u003c\/p\u003e \u003cul\u003e\n\u003cli\u003e12 clinically relevant CNVs associated with solid tumors\u003c\/li\u003e\n\u003cli\u003eA single reference material carrying gene amplifications at various levels\u003c\/li\u003e\n\u003cli\u003eCopy numbers quantified using sensitive dPCR assays and blended with the well-characterized GM24385 genomic background\u003c\/li\u003e\n\u003cli\u003eValidated by a targeted NGS panel• Manufactured in GMP-compliant, ISO 13485-certified facilities\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eSpecifications\u003c\/h2\u003e\u003ctable\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e# of CNVs\u003c\/td\u003e\n\u003ctd\u003e12 (AKT2, BRAF, EGFR, ERBB2, FGFR3, KIT, KRAS, MET, MYC, MYCN, NTRK1, PIK3CA)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCopy Numbers\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;3 copies of each gene\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFormat\u003c\/td\u003e\n\u003ctd\u003eFFPE\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSize\u003c\/td\u003e\n\u003ctd\u003e1 x 10 µm curl\/vial\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDNA Yield\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;100 ng\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e\u003ch2\u003eDocuments\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/mkt-00929-rev-1.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq® FFPE Solid Tumor CNV Reference Materials (Product Sheet)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/ps-0710-2865-seraseq-ffpe-solid-tumor-cnv-rm-mkt-00883-rev-1.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq FFPE Solid Tumor CNV RM Product Sheet (Product Sheet)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/pi-0710-2865-seraseq-ffpe-solid-tumor-cnv.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq FFPE Solid Tumor CNV RM Package Insert (Package Insert)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/ts-0710-2865-seraseq-ffpe-solid-tumor-cnv-rm.xlsx\" target=\"_blank\" rel=\"noopener\"\u003eTechnical Spreadsheet for Seraseq FFPE Solid Tumor CNV Reference Material and Seraseq Solid Tumor CNV Mixes (Technical Spreadsheet)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/sds-seraseq-ffpe.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq FFPE Safety Data Sheet (Safety Data Sheet)\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eOrdering Information\u003c\/h2\u003e\u003ctable\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eCat. no.\u003c\/th\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eSize\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\u003ctr\u003e\n\u003ctd\u003e0710-2865\u003c\/td\u003e\n\u003ctd\u003eSeraseq® FFPE Solid Tumor CNV Reference Materials\u003c\/td\u003e\n\u003ctd\u003e1 x 10 µm\u003c\/td\u003e\n\u003c\/tr\u003e\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"SeraCare","offers":[{"title":"Default Title","offer_id":46798512455759,"sku":"0710-2865","price":0.0,"currency_code":"ILS","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0712\/0748\/5519\/files\/0710-2865.jpg?v=1789655892"},{"product_id":"seracare-seraseq-hrd-gdna-mix-0710-2879","title":"Seraseq® HRD gDNA Mix","description":"\u003cp\u003eGenomic instability resulting from homologous recombination DNA repair deficiency (HRD) is a response biomarker to assess ovarian and breast cancer patient eligibility for PARP inhibitor and platinum-based therapies. HRD measurements have the potential to improve cancer therapy, however standardizing and democratizing HRD measurements remains challenging due to their inherent complexity. This cell line-derived HRD reference material can support the development, validation, and routine use of assays determining HRD status in cancer patients.\u003c\/p\u003e\u003cp\u003eFEATURES\u003c\/p\u003e\u003cp\u003e\u003c\/p\u003e\u003cli\u003eDerived from tumor and matched-normal human cell lines\u003c\/li\u003e\u003cli\u003eAllows blending to desired % tumor content with included SNP-matched normal cell line gDNA\u003c\/li\u003e\u003cli\u003e20 µL of both tumor and matched normal gDNA at 25 ng\/µL\u003c\/li\u003e\u003cli\u003eAdditional biosynthetic single-nucleotide variants (SNVs) of 4 homologous recombination repair (HRR) genes\u003c\/li\u003e\u003cli\u003eHRD status validated by targeted Next Generation Sequencing (NGS)\u003c\/li\u003e\u003cli\u003eManufactured in GMP-compliant, ISO 13485-certified facilities\u003c\/li\u003e\u003ch2\u003eDocuments\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/ps-0710-2879.2880.2881-seraseq-gdna-hrd-mix.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq gDNA HRD Mix Product Sheet (Product Sheet)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/pi-0710-2879.2880.2881-seraseq-gdna-hrd-mix.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq gDNA HRD Mix (Package Insert)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/tss-0710-2879.2880.2881-seraseq-gdna-hrd-mix.xlsx\" target=\"_blank\" rel=\"noopener\"\u003eTechnical Spreadsheet for Seraseq HRD Reference Materials (Technical Spreadsheet)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/nrl-0710-2879-2881-seraseq-hrd-gdna.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq gDNA HRD Mix Non-Requirement Lette (SDS Non-Requirement Letter)\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eOrdering Information\u003c\/h2\u003e\u003ctable\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eCat. no.\u003c\/th\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eSize\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e0710-2879\u003c\/td\u003e\n\u003ctd\u003eSeraseq® HRD gDNA High-Positive Mix\u003c\/td\u003e\n\u003ctd\u003e2 x 20 µL\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e0710-2880\u003c\/td\u003e\n\u003ctd\u003eSeraseq® HRD gDNA Low-Positive Mix\u003c\/td\u003e\n\u003ctd\u003e2 x 20 µL\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e0710-2881\u003c\/td\u003e\n\u003ctd\u003eSeraseq® HRD gDNA Negative Mix\u003c\/td\u003e\n\u003ctd\u003e2 x 20 µL\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"SeraCare","offers":[{"title":"High-Positive","offer_id":46798512685135,"sku":"0710-2879","price":0.0,"currency_code":"ILS","in_stock":true},{"title":"Low-Positive","offer_id":46798512717903,"sku":"0710-2880","price":0.0,"currency_code":"ILS","in_stock":true},{"title":"Negative","offer_id":46798512750671,"sku":"0710-2881","price":0.0,"currency_code":"ILS","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0712\/0748\/5519\/files\/0710-2879.jpg?v=1789655899"},{"product_id":"seracare-seraseq-unmethylated-ctdna-mutation-mix-0710-3088","title":"Seraseq® Unmethylated ctDNA Mutation Mix","description":"\u003cp\u003eThe use of ctDNA in the study and treatment of cancer continues to expand. Recent advances have highlighted CpG methylation of ctDNA a biomarker with multiple utilities. Methylation status gives insight to tumor recurrence, epigenetic regulation of gene expression and may also indicate tissue of origin of ctDNA.\u003c\/p\u003e\u003cp\u003eDespite the impactful layer of information methylation status adds to base-pair level sequencing data and the proliferation of assays to incorporate methylation data, reference materials have been limited compared to other areas of oncology.Seraseq Unmethylated ctDNA Mutation Mix is a low background ctDNA reference material comprised of ctDNA that is unmethylated (\u0026lt;2% detectably methylation) at all cpg sites. it can be used on its own or blended with seraseq methylated ctdna mutation mix to create a desired percent methylated ctdna profile.\u0026gt;\u003c!--2%--\u003e\u003c\/p\u003e\u003ch2\u003eDocuments\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/mkt-00961-01_methylated-ctdna-0710-3088-3089.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq Methylated ctDNA Mutation Mix (Product Sheet)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/pi-0710-3088-seraseq-unmethylated-ctdna-mix.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq Unmethylated ct Package InsertMix (Package Insert)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/nrl-0710-3088.3089.3181-3184-seraseq-ctdna-mutation-mix.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq ctDNA Mutation Mix Non-Requirement Letter (SDS Non-Requirement Letter)\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eOrdering Information\u003c\/h2\u003e\u003ctable\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eCat. no.\u003c\/th\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eSize\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\u003ctr\u003e\n\u003ctd\u003e0710-3088\u003c\/td\u003e\n\u003ctd\u003eSeraseq® Unmethylated ctDNA Mutation Mix\u003c\/td\u003e\n\u003ctd\u003e1 x 25 µL\u003c\/td\u003e\n\u003c\/tr\u003e\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"SeraCare","offers":[{"title":"Default Title","offer_id":46798512848975,"sku":"0710-3088","price":0.0,"currency_code":"ILS","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0712\/0748\/5519\/files\/0710-3088.jpg?v=1789655902"},{"product_id":"seracare-seraseq-methylated-ctdna-mutation-mix-0710-3089","title":"Seraseq® Methylated ctDNA Mutation Mix","description":"\u003cp\u003eThe use of ctDNA in the study and treatment of cancer continues to expand. Recent advances have highlighted CpG methylation of ctDNA a biomarker with multiple utilities. Methylation status gives insight to tumor recurrence, epigenetic regulation of gene expression and may also indicate tissue of origin of ctDNA.\u003c\/p\u003e\u003cp\u003eDespite the impactful layer of information methylation status adds to base-pair level sequencing data and the proliferation of assays to incorporate methylation data, reference materials have been limited compared to other areas of oncology.Seraseq Methylated ctDNA Mutation Mix is a low background ctDNA reference material comprised of ctDNA that is methylated (\u0026gt;90% detectable methylation) at all CpG sites. It can be used on its own or blended with Seraseq unmethylated ctDNA Mutation Mix to create a desired percent methylated ctDNA profile.\u003c\/p\u003e\u003ch2\u003eDocuments\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/mkt-00961-01_methylated-ctdna-0710-3088-3089.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq Methylated ctDNA Mutation Mix (Product Sheet)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/pi-0710-3089-seraseq-methylated-ctdna-mix.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq Methylated ctDNA Mutation Mix Product Insert (Package Insert)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/nrl-0710-3088.3089.3181-3184-seraseq-ctdna-mutation-mix.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq ctDNA Mutation Mix Non-Requirement Letter (SDS Non-Requirement Letter)\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eOrdering Information\u003c\/h2\u003e\u003ctable\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eCat. no.\u003c\/th\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eSize\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\u003ctr\u003e\n\u003ctd\u003e0710-3089\u003c\/td\u003e\n\u003ctd\u003eSeraseq® Methylated ctDNA Mutation Mix\u003c\/td\u003e\n\u003ctd\u003e1 x 25 µL\u003c\/td\u003e\n\u003c\/tr\u003e\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"SeraCare","offers":[{"title":"Default Title","offer_id":46798512816207,"sku":"0710-3089","price":0.0,"currency_code":"ILS","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0712\/0748\/5519\/files\/0710-3089.jpg?v=1789655905"},{"product_id":"seracare-seraseq-ctdna-mutation-mix-v4-0710-3100","title":"Seraseq® ctDNA Mutation Mix v4","description":"\u003cp\u003eAs liquid biopsy assays gain acceptance for a growing variety of clinical applications, an acute need for highly multiplexed reference materials bearing a broad range of clinically relevant variant types has arisen. But searching for useful remnant patient specimens is prohibitively time-consuming, and single plex cell lines are inefficient and add unnecessary expense.\u003c\/p\u003e\n\u003cp\u003eSeraseq ctDNA v4 reference materials are purpose-built to accelerate the thorough validation and clinical implementation of NGS-based ctDNA assays. Seraseq ctDNA v4 contains an unprecedented 93 variants including SNPs, indels, translocations and CNVs. Seraseq ctDNA v4 is manufactured with a new fragmentation process which results lower background than previous Seraseq ctDNA offerings to support greater confidence at low variant allele frequencies. These orthogonally validated truth-set materials can trim weeks or even months off your assay validation timeline with the most complete coverage of actionable variant types in a single reference sample. With the input of recognized clinical genomics experts, the Seraseq ctDNA v4 Reference Materials focus on clinically relevant variants that provide actionable feedback about patient samples.\u003c\/p\u003e\n\u003cp\u003eFEATURES AND BENEFITS\u003c\/p\u003e\n\u003cp\u003e93 unique multiplexed variants in 71 genes, covering 43 SNVs, 19 deletions, 5 insertions, 4 INDELs, 12 CNVs, and 10 translocations for the broadest coverage of clinically relevant variant types in a single reference material\u003c\/p\u003e\n\u003cp\u003eFour different variant allele frequencies (VAF) – WT (0%), 0.1%, 0.5%, and 5% - challenge your limit-of-detection or match typical AF of solid tumor NGS assays\u003c\/p\u003e\u003ch2\u003eSpecifications\u003c\/h2\u003e\u003ctable\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFragment Size\u003c\/td\u003e\n\u003ctd\u003e155-200 bp peak\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eConcentration\u003c\/td\u003e\n\u003ctd\u003e10 ng\/µL\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFill Volume\u003c\/td\u003e\n\u003ctd\u003e25 µL\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAmount\u003c\/td\u003e\n\u003ctd\u003e250 ng (single vial)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e# of Vials\u003c\/td\u003e\n\u003ctd\u003e1\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMatrix\u003c\/td\u003e\n\u003ctd\u003ePurified DNA in Buffer (Tris\/EDTA)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e\u003ch2\u003eDocuments\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/ps-0710-3097.3099.3100.3101-seraseq-ctdna-mutation-mix-v4.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq ctDNA v4 Reference Materials Product Sheet (Product Sheet)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/pi-0710-3097.3099.3100.3101-seraseq-ctdna-mutation-mix-v4.pdf\" target=\"_blank\" rel=\"noopener\"\u003ePackage Insert for Seraseq ctDNA Mutation Mix v4 (Package Insert)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/ts-0710-3097.3099.3100.3101-seraseq-ctdna-mutation-mix-v4.xlsx\" target=\"_blank\" rel=\"noopener\"\u003eTechnical Spreadsheet for Seraseq® ctDNA v4 Reference Materials (Technical Spreadsheet)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/nrl-0710-3088.3089.3181-3184-seraseq-ctdna-mutation-mix.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq ctDNA Mutation Mix Non-Requirement Letter (SDS Non-Requirement Letter)\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eOrdering Information\u003c\/h2\u003e\u003ctable\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eCat. no.\u003c\/th\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eSize\u003c\/th\u003e\n\u003cth\u003e# of Variants\u003c\/th\u003e\n\u003cth\u003eAllele Frequency\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e0710-3100\u003c\/td\u003e\n\u003ctd\u003eSeraseq® ctDNA Mutation Mix v4 AF5%\u003c\/td\u003e\n\u003ctd\u003e1 x 25 µL\u003c\/td\u003e\n\u003ctd\u003e93\u003c\/td\u003e\n\u003ctd\u003e5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e0710-3099\u003c\/td\u003e\n\u003ctd\u003eSeraseq® ctDNA Mutation Mix v4 AF0.5%\u003c\/td\u003e\n\u003ctd\u003e1 x 25 µL\u003c\/td\u003e\n\u003ctd\u003e93\u003c\/td\u003e\n\u003ctd\u003e0.5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e0710-3097\u003c\/td\u003e\n\u003ctd\u003eSeraseq® ctDNA Mutation Mix v4 AF0.1%\u003c\/td\u003e\n\u003ctd\u003e1 x 25 µL\u003c\/td\u003e\n\u003ctd\u003e93\u003c\/td\u003e\n\u003ctd\u003e0.1%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e0710-3101\u003c\/td\u003e\n\u003ctd\u003eSeraseq® ctDNA Mutation Mix v4 WT\u003c\/td\u003e\n\u003ctd\u003e1 x 25 µL\u003c\/td\u003e\n\u003ctd\u003e0 (Wild-Type)\u003c\/td\u003e\n\u003ctd\u003eWild-Type\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"SeraCare","offers":[{"title":"AF5%","offer_id":46798512914511,"sku":"0710-3100","price":0.0,"currency_code":"ILS","in_stock":true},{"title":"AF0.5%","offer_id":46798512947279,"sku":"0710-3099","price":0.0,"currency_code":"ILS","in_stock":true},{"title":"AF0.1%","offer_id":46798512980047,"sku":"0710-3097","price":0.0,"currency_code":"ILS","in_stock":true},{"title":"WT","offer_id":46798513012815,"sku":"0710-3101","price":0.0,"currency_code":"ILS","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0712\/0748\/5519\/files\/0710-3100.jpg?v=1789655911"},{"product_id":"seracare-seraseq-ctdna-extraction-reference-material-0710-3294","title":"Seraseq® ctDNA Extraction Reference Material","description":"\u003cp\u003ePreparation of a liquid biopsy sample starts with a blood draw from a patient followed by extraction of cfDNA from plasma. The concentration of cfDNA in a blood draw can vary greatly from patient to patient, but reference materials are typically built to a single cfDNA concertation. Additionally, extraction kits do not provide robust feedback about root cause of extractions resulting in lower than expected yield which increases the challenge of decoupling extraction kit performance from pre-analytic sample handling.\u003c\/p\u003e\n\u003cp\u003eLGC Clinical Diagnostics has produced the Seraseq ctDNA Extraction Reference Materials to allow clinical labs to validate and assess performance of cfDNA extractions in a more comprehensive manner. The ctDNA Extraction Reference Materials are available at concentrations of 20, 50 and 80 ng\/mL in synthetic plasma. In addition to being useful as total cfDNA extraction reference materials, the samples contain four EGFR variants present at 1% ctDNA to represent tumor ctDNA. Each kit comes with 4x single-use vials for ease of use at an affordable price point.\u003c\/p\u003e\u003ch2\u003eDocuments\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/ps-0710-3294-seraseq-ctdna-extraction-rm-20.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq® ctDNA Extraction Reference Material 20 ng\/mL Product Sheet (Product Sheet)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/ps-0710-3295-seraseq-ctdna-extraction-rm-50.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq® ctDNA Extraction Reference Material 50 ng\/mL Product Sheet (Product Sheet)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/ps-0710-3296-seraseq-ctdna-extraction-rm-80.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq ctDNA Extraction Reference Material 80 ng\/mL Product Sheet (Product Sheet)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/pi-0710-3294.3295.3296-seraseq-ctnda-extraction-rm-20-50-80-ng-per-ml.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq® ctDNA Extraction Reference Material 20 ng\/mL, 50 ng\/mL, 80 ng\/mL (Package Insert)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/ts-0710-3294.3295.3296-seraseq-ctdna-extraction-reference-material.xlsx\" target=\"_blank\" rel=\"noopener\"\u003eTechnical Spreadhseet for Seraseq ctDNA Extraction Reference Material (Technical Spreadsheet)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/nrl-0710-3294-3296-seraseq-ctdna-extraction-reference-material.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq ctDNA Extraction Reference Material Non-Requirement Letter (SDS Non-Requirement Letter)\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eOrdering Information\u003c\/h2\u003e\u003ctable\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eCat. no.\u003c\/th\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eSize\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e0710-3294\u003c\/td\u003e\n\u003ctd\u003eSeraseq® ctDNA Extraction Reference Material 20 ng\/ml\u003c\/td\u003e\n\u003ctd\u003e4 x 1 mL\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e0710-3295\u003c\/td\u003e\n\u003ctd\u003eSeraseq® ctDNA Extraction Reference Material 50 ng\/mL\u003c\/td\u003e\n\u003ctd\u003e4 x 1 mL\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e0710-3296\u003c\/td\u003e\n\u003ctd\u003eSeraseq® ctDNA Extraction Reference Material 80 ng\/mL\u003c\/td\u003e\n\u003ctd\u003e4 x 1 mL\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"SeraCare","offers":[{"title":"20 ng\/mL","offer_id":46798513242191,"sku":"0710-3294","price":0.0,"currency_code":"ILS","in_stock":true},{"title":"50 ng\/mL","offer_id":46798513274959,"sku":"0710-3295","price":0.0,"currency_code":"ILS","in_stock":true},{"title":"80 ng\/mL","offer_id":46798513307727,"sku":"0710-3296","price":0.0,"currency_code":"ILS","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0712\/0748\/5519\/files\/0710-3294.jpg?v=1789655918"},{"product_id":"seracare-seraseq-ctdna-lymphoma-mix-0710-3182","title":"Seraseq® ctDNA Lymphoma Mix","description":"\u003cp\u003eTo help clinical labs performing NGS-based lymphoid testing better develop, characterize, validate and routinely assess lymphoid diseases by NGS assays, SeraCare has developed the Seraseq® Lymphoma DNA Mutation Mix, Seraseq FFPE Lymphoma Reference Material and SeraSeq ctDNA Lymphoma DNA Mutation Mix,, the first set of comprehensive lymphoid cancer NGS assay reference materials. These unique products include clinically important SNVs, INDELs and gene fusions important in lymphoma disease diagnosis and prognosis. Variants are present against a single well-characterized genomic background (GM24385) at clinically relevant allele frequencies, precisely quantitated by digital PCR assays.\u003c\/p\u003e\u003cp\u003eFEATURES AND BENEFITS\u003c\/p\u003e\u003cli\u003eDevelop and validate Lymphoid-based NGS assays with confidence using a highly multiplexed reference material containing biomarkers important in Lymphoma cancers.\u003c\/li\u003e\u003cli\u003eProvide robust sensitivity to detect clinically-relevant mutations at variant allele frequencies that establish and validate assay LoD claims.\u003c\/li\u003e\u003cli\u003eMutation targets are quantitated using highly sensitive digital PCR as well as a custom NGS assay.\u003c\/li\u003e\u003cli\u003eAll mutations are blended against GM24385 human genomic DNA as background ‘wild-type’ material.\u003c\/li\u003e\u003cli\u003eAvailable as purified gDNA, ctDNA, and FFPE curls for end-to-end assay performance monitoring\u003c\/li\u003e\u003cli\u003eManufactured in GMP-compliant and ISO 13485-certified facilities.\u003c\/li\u003e\u003ch2\u003eDocuments\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/ps-mkt-00631-04-0710-31810710-31820710-31830710-3184.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq® Lymphoma DNA Products (Product Sheet)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/pi-0710-3181.3182.3183.3184-ctdna-lymphoma-mix-af1-af0.5-af0.1.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq® ctDNA Lymphoma Mix, AF1%, AF0.5%, AF0.1% (Package Insert)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/tss-0710-3181.3182.3183.3184-ctdna-lymphoma-mix-af1-af0.5-af0.1.xlsx\" target=\"_blank\" rel=\"noopener\"\u003eTechnical Spreadsheet for Seraseq ctDNA Lymphoma Mix (Technical Spreadsheet)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/nrl-0710-3088.3089.3181-3184-seraseq-ctdna-mutation-mix.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq ctDNA Mutation Mix Non-Requirement Letter (SDS Non-Requirement Letter)\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eOrdering Information\u003c\/h2\u003e\u003ctable\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eCat. no.\u003c\/th\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eSize\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e0710-3182\u003c\/td\u003e\n\u003ctd\u003eSeraseq® ctDNA Lymphoma Mix AF1%\u003c\/td\u003e\n\u003ctd\u003e1 x 25 µL\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e0710-3183\u003c\/td\u003e\n\u003ctd\u003eSeraseq® ctDNA Lymphoma Mix AF05\u003c\/td\u003e\n\u003ctd\u003e1 x 25 µL\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e0710-3184\u003c\/td\u003e\n\u003ctd\u003eSeraseq® ctDNA Lymphoma Mix AF01.%\u003c\/td\u003e\n\u003ctd\u003e1 x 25 µL\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e0710-3181\u003c\/td\u003e\n\u003ctd\u003eSeraseq® ctDNA Lymphoma Mix WT\u003c\/td\u003e\n\u003ctd\u003e1 x 25 µL\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"SeraCare","offers":[{"title":"AF1%","offer_id":46798513111119,"sku":"0710-3182","price":0.0,"currency_code":"ILS","in_stock":true},{"title":"AF0.5%","offer_id":46798513143887,"sku":"0710-3183","price":0.0,"currency_code":"ILS","in_stock":true},{"title":"AF0.1%","offer_id":46798513176655,"sku":"0710-3184","price":0.0,"currency_code":"ILS","in_stock":true},{"title":"WT","offer_id":46798513209423,"sku":"0710-3181","price":0.0,"currency_code":"ILS","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0712\/0748\/5519\/files\/0710-3182.jpg?v=1789655918"},{"product_id":"seracare-seraseq-ctdna-prostate-mix-0710-3328","title":"Seraseq® ctDNA Prostate Mix","description":"\u003cp\u003eINTRODUCTION\u003c\/p\u003e\n\u003cp\u003eWhile early-stage prostate cancer is often able to be surgically cured, castration resistant metastatic prostate cancer (mCRPC) is a difficult disease to manage with a 5-year survival rate of about 30%. Recent advances have shown that mCRPC can be managed with PARP inhibitor therapy if there are appropriate homologous recombination repair (HRR) gene mutation present in the tumor.\u003c\/p\u003e\n\u003cp\u003eLGC Clinical Diagnostics has produced the Seraseq ctDNA Prostate Mix to aid in labs wanting to know the HRR status of ctDNA from mCRPC as well as survey for canonical mutations to monitor for recurrence of disease. The diverse set of 48 mutations present include SNVs, insertions, deletions, indels, duplications, translocations and CNVs making this the best-in-class reference material on the market.\u003c\/p\u003e\n\u003cp\u003eFEATURES AND BENEFITS\u003c\/p\u003e\n\u003cp\u003e• Validate and monitor performance of cfDNA prostate cancer assays using well defined, precisely built reference materials\u003c\/p\u003e\n\u003cp\u003e• Variants present at 1% or 0.5% Variant Allele Frequency (VAF)\u003c\/p\u003e\n\u003cp\u003e• Mutation targets are quantitated using highly sensitive digital PCR\u003c\/p\u003e\n\u003cp\u003e• Orthogonal NGS data as well to support variant allele frequencies present and compare between assays\u003c\/p\u003e\n\u003cp\u003e• Affordably priced for routine use\u003c\/p\u003e\n\u003cp\u003e• All mutations are blended against GM24385 human genomic DNA as background ‘wild type’ material\u003c\/p\u003e\n\u003cp\u003e• Manufactured in GMP-compliant and ISO 13485-certified facilities\u003c\/p\u003e\u003ch2\u003eSpecifications\u003c\/h2\u003e\u003ctable\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e# of Variants\u003c\/td\u003e\n\u003ctd\u003e48\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFragment Size\u003c\/td\u003e\n\u003ctd\u003e155-220 bp peak\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eConcentration\u003c\/td\u003e\n\u003ctd\u003e10 ng\/µL\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFill Volume\u003c\/td\u003e\n\u003ctd\u003e25 µL\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAmount\u003c\/td\u003e\n\u003ctd\u003e250 ng (single vial)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e# of Vials\u003c\/td\u003e\n\u003ctd\u003e1\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMatrix\u003c\/td\u003e\n\u003ctd\u003ePurified DNA in Buffer (Tris\/EDTA)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e\u003ch2\u003eDocuments\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/ps-0710-3327.3328.3329-seraseq-ctdna-prostate-reference-materials.pdf\" target=\"_blank\" rel=\"noopener\"\u003eProduct Sheet for Seraseq ctDNA Prostate Mix (Product Sheet)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/pi-0710-3327.3328.3329-serasaeq-ctdna-prostate-mix.pdf\" target=\"_blank\" rel=\"noopener\"\u003ePackage Insert for Seraseq ctDNA Prostate Mix (Package Insert)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/ts-0710-3327.3328.3329-serasaeq-ctdna-prostate-mix.xlsx\" target=\"_blank\" rel=\"noopener\"\u003eTechnical Spreadsheet for Seraseq ctDNA Prostate Mix (Technical Spreadsheet)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/nrl-seraseq-ctdna-prostate-mix.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq ctDNA Prostate Mix Non-Requirement Letter (SDS Non-Requirement Letter)\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eOrdering Information\u003c\/h2\u003e\u003ctable\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eCat. no.\u003c\/th\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eSize\u003c\/th\u003e\n\u003cth\u003eAllele Frequency\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e0710-3328\u003c\/td\u003e\n\u003ctd\u003eSeraseq® ctDNA Prostate Mix AF1%\u003c\/td\u003e\n\u003ctd\u003e1 x 25 µL\u003c\/td\u003e\n\u003ctd\u003e1% VAF\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e0710-3329\u003c\/td\u003e\n\u003ctd\u003eSeraseq® ctDNA Prostate Mix AF0.5%\u003c\/td\u003e\n\u003ctd\u003e1 x 25 µL\u003c\/td\u003e\n\u003ctd\u003e0.5% VAF\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e0710-3327\u003c\/td\u003e\n\u003ctd\u003eSeraseq® ctDNA Prostate Mix WT\u003c\/td\u003e\n\u003ctd\u003e1 x 25 µL\u003c\/td\u003e\n\u003ctd\u003eWT\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"SeraCare","offers":[{"title":"AF1%","offer_id":46798513406031,"sku":"0710-3328","price":0.0,"currency_code":"ILS","in_stock":true},{"title":"AF0.5%","offer_id":46798513438799,"sku":"0710-3329","price":0.0,"currency_code":"ILS","in_stock":true},{"title":"WT","offer_id":46798513471567,"sku":"0710-3327","price":0.0,"currency_code":"ILS","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0712\/0748\/5519\/files\/0710-3328.jpg?v=1789655924"},{"product_id":"seracare-seraseq-tumor-mutation-dna-mix-v3-0710-3460","title":"Seraseq® Tumor Mutation DNA Mix v3","description":"\u003cp\u003eSeraCare continues to lead in providing innovative, fit-for-purpose reference standards to meet the evolving needs of NGS assays. The Seraseq® Tumor Mutation Mix DNA v3 AF10% reference material represents one of our most complex products to date, containing the highest number of biosynthetic variants in a single mix. It is specifically designed to support NGS assay development, validation, and routine QC monitoring.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSeraseq® Tumor Mutation Mix DNA v3\u003c\/strong\u003e \u003cstrong\u003eAF10%\u003c\/strong\u003e contains 112 variants across 92 genes, including key tumor suppressors, oncogenes, DNA repair and cell cycle regulators. These biosynthetic variants are blended into a well-characterized GM24385 background. This ready-to-use material is optimized for use in NGS workflows following DNA extraction through to downstream analysis. Manufactured under cGMP-compliant ISO 13485-certified facilities, this reference material ensures lot-to-lot consistency and accuracy, ultimately supporting high-quality genomic testing outcomes. \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eFEATURES and BENEFITS \u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e112 unique multiplexed biosynthetic DNA variants across 92 genes in a single reference material \n\u003cul\u003e\n\u003cli\u003e51 SNVs\u003c\/li\u003e\n\u003cli\u003e39 Indels\u003c\/li\u003e\n\u003cli\u003e10 Translocations\u003c\/li\u003e\n\u003cli\u003e12 CNVs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e94 variants recognized as FDA drug targets support comprehensive detection of clinically actionable mutations \u003c\/li\u003e\n\u003cli\u003eAll variants are targeted at a VAF of 10% and CNVs at +12 copies\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cul\u003e\n\u003cli\u003eMutation targets quantified by highly sensitive digital PCR and orthogonally validated by NGS \u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cul\u003e\n\u003cli\u003eBlended with well-characterized GM24385 human genomic DNA as background wildtype material \u003c\/li\u003e\n\u003cli\u003eSupport assay validation studies including determination of assay sensitivity, specificity and Limit of Detection (LoD)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cul\u003e\n\u003cli\u003eManufactured under cGMP-compliance and ISO 13485-certified facilities \u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eSpecifications\u003c\/h2\u003e\u003ctable\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGenes\u003c\/td\u003e\n\u003ctd\u003e92\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e# of Variants\u003c\/td\u003e\n\u003ctd\u003e112 (refer to resources tab for more details)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eConcentration\u003c\/td\u003e\n\u003ctd\u003e25 ng\/µL\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFill Volume\u003c\/td\u003e\n\u003ctd\u003e15 µL\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAmount\u003c\/td\u003e\n\u003ctd\u003e375 ng (single vial)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e# of Vials\u003c\/td\u003e\n\u003ctd\u003e1\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMatrix\u003c\/td\u003e\n\u003ctd\u003e1 mM Tris, 0.1 mM EDTA pH 8.0\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e\u003ch2\u003eDocuments\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/ps-0710-3460.3461.3462-seraseq-tumor-mutation-dna-mix-v3.pdf\" target=\"_blank\" rel=\"noopener\"\u003eProduct Sheet for Seraseq Tumor Mutation DNA Mix v3 (Product Sheet)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/ds-0710-3460.3461.3462-seraseq-tumor-mutation-dna-mix-v3.pdf\" target=\"_blank\" rel=\"noopener\"\u003eData Sheet for Seraseq Tumor Mutation DNA Mix v3 (Data Sheet)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/pi-0710-3460.3461.3462-seraseq-tumor-mutation-dna-mix-v3.pdf\" target=\"_blank\" rel=\"noopener\"\u003ePackage Insert for Seraseq Tumor Mutation DNA Mix v3 (Package Insert)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/ts-0710-3460.3461.3462-seraseq-tumor-mutation-dna-mix-v3.xlsx\" target=\"_blank\" rel=\"noopener\"\u003eTechnical Spreadsheet for Seraseq Tumor Mutation DNA Mix v3 (Technical Spreadsheet)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/nrl-seraseq-tumor-mutation-dna-mix-v3.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq Tumor Mutation DNA Mix v3 Non-Requirement Letter (SDS Non-Requirement Letter)\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eOrdering Information\u003c\/h2\u003e\u003ctable\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eCat. no.\u003c\/th\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eSize\u003c\/th\u003e\n\u003cth\u003eAllele Frequency\u003c\/th\u003e\n\u003cth\u003eCopy number\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e0710-3460\u003c\/td\u003e\n\u003ctd\u003eSeraseq® Tumor Mutation DNA Mix v3 AF10%\u003c\/td\u003e\n\u003ctd\u003e1 x 15 µL\u003c\/td\u003e\n\u003ctd\u003e7%\u003c\/td\u003e\n\u003ctd\u003e+6 copies\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e0710-3461\u003c\/td\u003e\n\u003ctd\u003eSeraseq® Tumor Mutation DNA Mix v3 AF7%\u003c\/td\u003e\n\u003ctd\u003e1 x 15 µL\u003c\/td\u003e\n\u003ctd\u003e7%\u003c\/td\u003e\n\u003ctd\u003e+6 copies\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e0710-3462\u003c\/td\u003e\n\u003ctd\u003eSeraseq® Tumor Mutation DNA Mix v3 Tri-Level\u003c\/td\u003e\n\u003ctd\u003e1 x 15 µL\u003c\/td\u003e\n\u003ctd\u003e4%, 7% and 10%\u003c\/td\u003e\n\u003ctd\u003e+3, +6 and +12 copies\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"SeraCare","offers":[{"title":"AF10%","offer_id":46798513602639,"sku":"0710-3460","price":0.0,"currency_code":"ILS","in_stock":true},{"title":"AF7%","offer_id":46798513635407,"sku":"0710-3461","price":0.0,"currency_code":"ILS","in_stock":true},{"title":"Tri-Level","offer_id":46798513668175,"sku":"0710-3462","price":0.0,"currency_code":"ILS","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0712\/0748\/5519\/files\/0710-3460.jpg?v=1789655927"},{"product_id":"seracare-seraseq-ctdna-esr1-mutation-mix-0710-3565","title":"Seraseq® ctDNA ESR1 Mutation Mix","description":"\u003cp\u003eThe ESR1 gene is frequently mutated in metastatic breast cancer (MBC), with 15-50% of all metastatic breast cancer patients harboring ESR1 mutations. ESR1 mutations develop in response to selection pressure during treatment and are typically undetectable in the primary tumor. The recent emergence and approval of drug therapy specific to ESR1 mutations in metastatic breast cancer have led to the updated guidance to monitor MBC patients for mutations in both ESR1 and PIK3CA to guide treatment decisions. Such mutations are often polyclonal and co-occurring, and most easily tracked in circulating tumor DNA (ctDNA) in liquid biopsy samples.\u003c\/p\u003e\n\u003cp\u003eSeraseq ctDNA ESR1 reference materials can help confirm the presence of clinically relevant ESR1 and PIK3CA variants including ones in the druggable ligand binding domain of ESR1. Care has been taken in the design of this reference material to include all DNA alterations which lead to the relevant changes to the amino acid sequence of the ESR1 protein to confirm detection of different variant types.\u003c\/p\u003e\n\u003cp\u003e• 22 clinically relevant mutations in ESR1 and PIK3CA\u003c\/p\u003e\n\u003cp\u003e• All variants present at 1% variant allele frequency (VAF) with WT sample available to dilute and challenge limit of detection\u003c\/p\u003e\n\u003cp\u003e• All DNA mutations leading to clinically relevant amino acid substitutions in the ligand binding domain of ESR1 (e.g. 3 different DNA sequences leading to a Y537S amino acid substitution) are present\u003c\/p\u003e\u003ch2\u003eSpecifications\u003c\/h2\u003e\u003ctable\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e# of Variants\u003c\/td\u003e\n\u003ctd\u003e22\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAllele Frequency\u003c\/td\u003e\n\u003ctd\u003e1%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFragment Size\u003c\/td\u003e\n\u003ctd\u003e155-200 bp peak\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eConcentration\u003c\/td\u003e\n\u003ctd\u003e10 ng\/µL\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFill Volume\u003c\/td\u003e\n\u003ctd\u003e25 µL\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAmount\u003c\/td\u003e\n\u003ctd\u003e250 ng (single vial)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e# of Vials\u003c\/td\u003e\n\u003ctd\u003e1\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMatrix\u003c\/td\u003e\n\u003ctd\u003ePurified DNA in Buffer (Tris\/EDTA)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e\u003ch2\u003eDocuments\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/ps-0710-3564.3565-seraseq-ctdna-esr1-mutation-mix-af1.pdf\" target=\"_blank\" rel=\"noopener\"\u003eProduct Sheet for Seraseq ctNDA ESR1 Mutation Mix (Product Sheet)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/pi-0710-3564.3565-seraseq-ctdna-esr1-mutation-mix.pdf\" target=\"_blank\" rel=\"noopener\"\u003ePackage Insert for Seraseq ctNDA ESR1 Mutation Mix (Package Insert)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/ts-0710-3564.3565-seraseq-ctdna-esr1-mutation-mix.xlsx\" target=\"_blank\" rel=\"noopener\"\u003eTechnical Spreadsheet for Serasaeq ctDNA ESR1 Mutation Mix (Technical Spreadsheet)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/nrl-seraseq-ctdna-esr1-mix.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq ctDNA ESR1 Mix Non-Requirement Letter (SDS Non-Requirement Letter)\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eOrdering Information\u003c\/h2\u003e\u003ctable\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eCat. no.\u003c\/th\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eSize\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e0710-3565\u003c\/td\u003e\n\u003ctd\u003eSeraseq® ctDNA ESR1 Mutation Mix AF1\u003c\/td\u003e\n\u003ctd\u003e1 x 250 ng\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e0710-3564\u003c\/td\u003e\n\u003ctd\u003eSeraseq® ctDNA ESR1 Mix WT\u003c\/td\u003e\n\u003ctd\u003e1 x 250 ng\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"SeraCare","offers":[{"title":"AF1%","offer_id":46798513537103,"sku":"0710-3565","price":0.0,"currency_code":"ILS","in_stock":true},{"title":"WT","offer_id":46798513569871,"sku":"0710-3564","price":0.0,"currency_code":"ILS","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0712\/0748\/5519\/files\/0710-3565.jpg?v=1789655931"},{"product_id":"seracare-seraseq-solid-tumor-ffpe-dna-reference-material-0710-3634","title":"Seraseq® Solid Tumor FFPE DNA Reference Material","description":"\u003cp\u003eTissue biopsy samples that are formalin-fixed and paraffin-embedded (FFPE) are widely used in comprehensive genomic profiling (CGP) for cancer diagnosis. However, due to the chemical modifications introduced during the fixation process, FFPE samples present unique challenges that can compromise sequencing results starting from pre-analytical extraction steps through to downstream analysis. To ensure the accurate identification of clinically actionable variants, high-quality reference materials are essential for guiding and validating data quality and accuracy throughout the sample-to-result assay process.\u003c\/p\u003e\n\u003cp\u003eSeraseq Solid Tumor FFPE DNA reference materials are expertly designed to mimic patient-like characteristics, enabling clinical labs and assay developers to confidently develop, validate, and routinely assess their solid tumor molecular assays. This unique product contains 74 biosynthetic DNA variants including SNVs, insertions, deletions, and translocations all within a single reference sample. By providing a realistic and reliable benchmark, this positive FFPE reference material enhances the accuracy of CGP assays and patient sample testing, supporting improved clinical decision-making in cancer care.\u003c\/p\u003e\n\u003cp\u003eFEATURES AND BENEFITS\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eHighly multiplexed containing 74 variants in 62 genes associated with solid tumors in a single sample.\u003c\/li\u003e\n\u003cli\u003eIncludes SNVs (37), INDELs (4), deletions (18), insertions (5) and translocations (10)\u003c\/li\u003e\n\u003cli\u003e65 variants are FDA drug targets\u003c\/li\u003e\n\u003cli\u003eFor use in sample-to-result NGS workflows to analyze for mutation-positive variants in patient samples\u003c\/li\u003e\n\u003cli\u003eManufactured in GMP-compliant and ISO 13485 certified facility\u003c\/li\u003e\n\u003cli\u003eMutation targets measured by targeted NGS panel with select key variants further validated by dPCR\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eSpecifications\u003c\/h2\u003e\u003ctable\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e# of Variants\u003c\/td\u003e\n\u003ctd\u003e74\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eConcentration\u003c\/td\u003e\n\u003ctd\u003e1 FFPE curl\/vial\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFill Volume\u003c\/td\u003e\n\u003ctd\u003e10 µm curl\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Mass\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;100 ng DNA*\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e# of Vials\u003c\/td\u003e\n\u003ctd\u003e1\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMatrix\u003c\/td\u003e\n\u003ctd\u003eFFPE\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e\u003ch2\u003eDocuments\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/ds-0710-3634-seraseq-solid-tumor-ffpe-dna-reference-material.pdf\" target=\"_blank\" rel=\"noopener\"\u003eProduct Sheet for Seraseq Solid Tumor FFPE DNA Reference Material (Product Sheet)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/pi-0710-3634-seraseq-solid-tumor-ffpe-dna-reference-material.pdf\" target=\"_blank\" rel=\"noopener\"\u003ePackage Insert for Seraseq Solid Tumor FFPE Reference Material (Package Insert)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/ts-0710-3634-seraseq-solid-tumor-ffpe-dna-reference-material.xlsx\" target=\"_blank\" rel=\"noopener\"\u003eTechnical Spreadsheet for Seraseq Solid Tumor FFPE DNA Reference Material (Technical Spreadsheet)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/sds-seraseq-ffpe.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq FFPE Safety Data Sheet (Safety Data Sheet)\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eOrdering Information\u003c\/h2\u003e\u003ctable\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eCat. no.\u003c\/th\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eSize\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\u003ctr\u003e\n\u003ctd\u003e0710-3634\u003c\/td\u003e\n\u003ctd\u003eSeraseq® Solid Tumor FFPE DNA Reference Material\u003c\/td\u003e\n\u003ctd\u003e1 x 10 µm\u003c\/td\u003e\n\u003c\/tr\u003e\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"SeraCare","offers":[{"title":"Default Title","offer_id":46798513897551,"sku":"0710-3634","price":0.0,"currency_code":"ILS","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0712\/0748\/5519\/files\/0710-3634.jpg?v=1789655938"},{"product_id":"seracare-seraseq-ctdna-mrd-mix-0710-3671","title":"Seraseq® ctDNA MRD Mix","description":"\u003cp\u003eMRD monitoring typically involves measuring signs of a cancer in order to inform decisions about treatment escalation and de-escalation. Typically, this can be facilitated by use of less invasive techniques such as liquid biopsy (ctDNA), to monitor cancer-specific somatic variants. A patient-derived approach to the application of ctDNA-based MRD monitoring starts with a tumor profiling analysis to identify clinically relevant tumor variants that constitute the patient’s genomic profile. Following this, a targeted panel\/assay containing a subset of the gene variants can be designed for disease monitoring by detecting presence or absence of circulating tumor (ct) DNA variants in the patient’s blood sample. These patient-derived MRD analyses represent a paradigm shift in disease monitoring and are rapidly being developed by many assay vendors while best clinical practices are being developed in parallel.\u003c\/p\u003e\n\u003cp\u003eSeraCare has developed a novel ctDNA MRD mutation mix designed to support the development, validation and clinical deployment of a ctDNA-based patient-derived MRD monitoring NGS assays. The new Seraseq ctDNA MRD Mix product is constructed from a combination of a diseased human cell line, its SNP-matched normal cell line, and biosynthetic DNA containing variants commonly targeted by therapeutic drugs. The blended DNA is fragmented, sized to mimic ctDNA fragment sizes, and serially diluted to tumor fraction (TF) of 0.5%.\u003c\/p\u003e\u003ch2\u003eSpecifications\u003c\/h2\u003e\u003ctable\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e# of Variants\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;600 exonic variants\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e# of Vials\u003c\/td\u003e\n\u003ctd\u003e1\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFill Volume\u003c\/td\u003e\n\u003ctd\u003e20 µL\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eConcentration\u003c\/td\u003e\n\u003ctd\u003e10 ng\/µl\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Mass\u003c\/td\u003e\n\u003ctd\u003e200 ng\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFormat\u003c\/td\u003e\n\u003ctd\u003ePurified DNA in buffer (Tris\/EDTA)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e\u003ch2\u003eDocuments\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/ps-0710-2146-mkt-00617-seraseq-ctdna-mrd-panel-mix.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq® ctDNA MRD Mix (Product Sheet)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/pi-0710-2146-seraseq-ctdna-mrd-panel-mix.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq ctDNA MRD Mix - Package Insert (Package Insert)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/nrl-seraseq-ctdna-mrd-tumor.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq ctDNA MRD Tumor Non-Requirement Letter (SDS Non-Requirement Letter)\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eOrdering Information\u003c\/h2\u003e\u003ctable\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eCat. no.\u003c\/th\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eSize\u003c\/th\u003e\n\u003cth\u003eTumor Level\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e0710-3671\u003c\/td\u003e\n\u003ctd\u003eSeraseq® ctDNA MRD 0.5% Tumor\u003c\/td\u003e\n\u003ctd\u003e1 x 20 µL\u003c\/td\u003e\n\u003ctd\u003e0.5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e0710-3672\u003c\/td\u003e\n\u003ctd\u003eSeraseq® ctDNA MRD 0.05% Tumor\u003c\/td\u003e\n\u003ctd\u003e1 x 20 µL\u003c\/td\u003e\n\u003ctd\u003e0.05%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e0710-3673\u003c\/td\u003e\n\u003ctd\u003eSeraseq® ctDNA MRD 0.005% Tumor\u003c\/td\u003e\n\u003ctd\u003e1 x 20 µL\u003c\/td\u003e\n\u003ctd\u003e0.005%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e0710-3670\u003c\/td\u003e\n\u003ctd\u003eSeraseq® ctDNA MRD 0% Tumor\u003c\/td\u003e\n\u003ctd\u003e1 x 20 µL\u003c\/td\u003e\n\u003ctd\u003e0%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"SeraCare","offers":[{"title":"0.5% Tumor","offer_id":46798513766479,"sku":"0710-3671","price":0.0,"currency_code":"ILS","in_stock":true},{"title":"0.05% Tumor","offer_id":46798513799247,"sku":"0710-3672","price":0.0,"currency_code":"ILS","in_stock":true},{"title":"0.005% Tumor","offer_id":46798513832015,"sku":"0710-3673","price":0.0,"currency_code":"ILS","in_stock":true},{"title":"0% Tumor","offer_id":46798513864783,"sku":"0710-3670","price":0.0,"currency_code":"ILS","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0712\/0748\/5519\/files\/0710-3671.jpg?v=1789655939"},{"product_id":"seracare-seraseq-sarcoma-plus-rna-fusion-mix-0710-3809","title":"Seraseq® Sarcoma Plus RNA Fusion Mix","description":"\u003cp\u003eAs diagnostic testing for chromosomal translocations and other complex structural variants continues to shift from single-site methods such as Fluorescent In Situ Hybridization (FISH) and targeted reverse transcription PCR (RT-PCR) to highly multiplexed next-generation sequencing (NGS) assays, there is an increasing need for highly multiplexed reference materials covering such alterations which may be rare or difficult to obtain from patient samples. SeraCare continues to innovate to address this critical market need with an expanded reference material designed for use with NGS assays that detect gene fusions via sequencing of RNA transcripts.\u003c\/p\u003e\n\u003cp\u003eSeraCare has long supported RNA fusion studies with many novel RNA fusion reference material offerings. Seraseq Sarcoma Plus RNA Fusion Mix is a new product which is complementary to existing RNA fusion product offerings.\u003c\/p\u003e\n\u003cp\u003eSeraseq Sarcoma Plus RNA Fusion Mix is a highly multiplexed pan-cancer RNA reference material containing 30 RNA fusion transcripts in a single sample. This will allow for more rapid validation of assays using fewer samples and more comprehensive performance monitoring of routine NGS runs.\u003c\/p\u003e\u003ch2\u003eSpecifications\u003c\/h2\u003e\u003ctable\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e# of Variants\u003c\/td\u003e\n\u003ctd\u003e30\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e# of Vials\u003c\/td\u003e\n\u003ctd\u003e1\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFill Volume\u003c\/td\u003e\n\u003ctd\u003e20 µL\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eConcentration\u003c\/td\u003e\n\u003ctd\u003e25 ng\/µl\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Mass\u003c\/td\u003e\n\u003ctd\u003e500 ng\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFormat\u003c\/td\u003e\n\u003ctd\u003ePurified RNA in buffer (Tris\/EDTA)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e\u003ch2\u003eDocuments\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/ps-0710-3809-seraseq-sarcoma-plus-rna-fusion-mix.pdf\" target=\"_blank\" rel=\"noopener\"\u003eProduct Sheet for Seraseq Sarcoma Plus RNA Fusion Mix (Product Sheet)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/pi-0710-3809-seraseq-sarcoma-plus-rna-fusion-mix.pdf\" target=\"_blank\" rel=\"noopener\"\u003ePackage Insert for Seraseq Sarcoma Plus RNA Fusion Mix (Package Insert)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/ts-0710-3809-seraseq-sarcoma-plus-rna-fusion-mix.xlsx\" target=\"_blank\" rel=\"noopener\"\u003eTechnical Spreadhseet for Seraseq Saracoma Plus RNA Fusion Mix (Technical Spreadsheet)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/nrl-0710-3809-seraseq-sarcoma-plus-rna-fusion-mix.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq Sarcoma Plus RNA Fusion Mix Non-Requirement Letter (SDS Non-Requirement Letter)\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eOrdering Information\u003c\/h2\u003e\u003ctable\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eCat. no.\u003c\/th\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eSize\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\u003ctr\u003e\n\u003ctd\u003e0710-3809\u003c\/td\u003e\n\u003ctd\u003eSeraseq® Sarcoma Plus RNA Fusion Mix\u003c\/td\u003e\n\u003ctd\u003e1 x 20 µL\u003c\/td\u003e\n\u003c\/tr\u003e\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"SeraCare","offers":[{"title":"Default Title","offer_id":46798514061391,"sku":"0710-3809","price":0.0,"currency_code":"ILS","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0712\/0748\/5519\/files\/0710-3809.jpg?v=1789655946"},{"product_id":"seracare-seraseq-euploid-matched-reference-material-0720-0169","title":"Seraseq® Euploid Matched Reference Material","description":"\u003cp\u003eNon-invasive prenatal testing (NIPT) continues to expand globally, and given the clinical implicatons, it is extremely critical that NIPT assays report back presence or absence of aneuploidies in an accurate and consistent manner. Matched maternal-fetal reference materials derived from pregnant maternal plasma enable accurate assessment of a broad range of NIPT assays, including those based on counting methods, SNPs, as well as differences in the length of maternal and fetal cfDNA. The Seraseq Euploid Male - Matched Reference Material can be used to develop a new test, validate an assay, monitor routine performance, troubleshoot problems across the entire workflow and ensure overall proficiency with the same sustainable product.- Matched (or related) maternal-fetal Euploid male sample compatible with a broad range of NIPT assay methods- Proprietary method maintains native cfDNA size profile of ~170 bp size distribution and natural maternal-fetal size difference- Offered in a plasma format capable of assessing the entire workflow from extraction through analysis (identical to clinical samples)- Fetal fraction levels confirmed to be moderate-high positive to help establish initial baseline (can be customized to lower levels)- Manufactured in GMP-compliant and ISO 13485-certified facilities\u003c\/p\u003e\u003ch2\u003eDocuments\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/ps-mkt-00506-seraseq-nipt-rm-brochure.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq NIPT Reference Materials (Product Sheet)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/pi-0720-0169-seraseq-euploid-male-matched-ref-mat.pdf\" target=\"_blank\" rel=\"noopener\"\u003ePackage Insert for Seraseq Euploid Male Matched Reference Material (Package Insert)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/pi-0720-0169-seraseq-euploid-male-matched-rm.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq Euploid Male Matched Reference Material (Package Insert)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/pi-0720-0170-seraseq-euploid-female-matched-rm.pdf\" target=\"_blank\" rel=\"noopener\"\u003ePackage Insert for Seraseq Euploid Female - Matched Reference Material (Package Insert)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/nrl-0710-0169-0174-seraseq-euploid.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq Euploid Reference Material Non-Requirement Letter (SDS Non-Requirement Letter)\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eOrdering Information\u003c\/h2\u003e\u003ctable\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eCat. no.\u003c\/th\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eSize\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e0720-0169\u003c\/td\u003e\n\u003ctd\u003eSeraseq® Euploid Male-Matched Reference Material\u003c\/td\u003e\n\u003ctd\u003e1 x 1 mL\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e0720-0170\u003c\/td\u003e\n\u003ctd\u003eSeraseq® Euploid Female-Matched Reference Material\u003c\/td\u003e\n\u003ctd\u003e1 x 1 mL\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"SeraCare","offers":[{"title":"Male","offer_id":46798514257999,"sku":"0720-0169","price":0.0,"currency_code":"ILS","in_stock":true},{"title":"Female","offer_id":46798514290767,"sku":"0720-0170","price":0.0,"currency_code":"ILS","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0712\/0748\/5519\/files\/0720-0169.jpg?v=1789655952"},{"product_id":"seracare-seraseq-trisomy-21-matched-reference-material-0720-0167","title":"Seraseq® Trisomy 21 Matched Reference Material","description":"\u003cp\u003eNon-invasive prenatal testing (NIPT) continues to expand globally, and given the clinical implications, it is extremely critical that NIPT assays report back presence or absence of aneuploidies in an accurate and consistent manner. Matched maternal-fetal reference materials derived from pregnant maternal plasma enable accurate assessment of a broad range of NIPT assays, including those based on counting methods, SNPs, as well as differences in the length of maternal and fetal cfDNA.\u003c\/p\u003e\u003cp\u003eThe Seraseq Trisomy 21 Male- Matched Reference Material can be used to develop a new test, validate an assay, monitor routine performance, troubleshoot problems across the entire workflow and ensure overall proficiency with the same sustainable product.\u003c\/p\u003e\u003cp\u003e\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eMatched (or related) maternal-fetal Trisomy 21 male sample compatible with a broad range of NIPT assay methods\u003c\/li\u003e\n\u003cli\u003eProprietary method maintains native cfDNA size profile of ~170 bp size distribution and natural maternal-fetal size difference\u003c\/li\u003e\n\u003cli\u003eOffered in a plasma format capable of assessing the entire workflow from extraction through analysis (identical to clinical samples)\u003c\/li\u003e\n\u003cli\u003eFetal fraction levels confirmed to be moderate-high positive to help establish initial baseline (can be customized to lower levels)\u003c\/li\u003e\n\u003cli\u003eManufactured in GMP-compliant and ISO 13485-certified facilities\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eDocuments\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/ps-mkt-00506-seraseq-nipt-rm-brochure.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq NIPT Reference Materials (Product Sheet)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/pi-0720-0167-seraseq-trisomy21-male-matched-rm.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq Trisomy 21 Male - Matched Reference Material (Package Insert)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/pi-0720-0168-seraseq-t21-female-matched-ref-mat.pdf\" target=\"_blank\" rel=\"noopener\"\u003ePackage Insert for Seraseq Trisomy 21 Female - Matched Reference Materials (Package Insert)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/nrl-0710-0167.0171.0172.0779.0780-seraseq-matched-reference-material.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq Matched Reference Material Non-Requirement Letter (SDS Non-Requirement Letter)\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eOrdering Information\u003c\/h2\u003e\u003ctable\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eCat. no.\u003c\/th\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eSize\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e0720-0167\u003c\/td\u003e\n\u003ctd\u003eSeraseq® Trisomy 21 Male-Matched Reference Material\u003c\/td\u003e\n\u003ctd\u003e1 x 1 mL\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e0720-0168\u003c\/td\u003e\n\u003ctd\u003eSeraseq® Trisomy 21 Female-Matched Reference Material\u003c\/td\u003e\n\u003ctd\u003e1 x 1 mL\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"SeraCare","offers":[{"title":"Male","offer_id":46798514192463,"sku":"0720-0167","price":0.0,"currency_code":"ILS","in_stock":true},{"title":"Female","offer_id":46798514225231,"sku":"0720-0168","price":0.0,"currency_code":"ILS","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0712\/0748\/5519\/files\/0720-0167.jpg?v=1789655952"},{"product_id":"seracare-seraseq-trisomy-18-matched-reference-material-0720-0171","title":"Seraseq® Trisomy 18 Matched Reference Material","description":"\u003cp\u003eNon-invasive prenatal testing (NIPT) continues to expand globally, and given the clinical implicatons, it is extremely critical that NIPT assays report back presence or absence of aneuploidies in an accurate and consistent manner. Matched maternal-fetal reference materials derived from pregnant maternal plasma enable accurate assessment of a broad range of NIPT assays, including those based on counting methods, SNPs, as well as differences in the length of maternal and fetal cfDNA.\u003c\/p\u003e\u003cp\u003eThe Seraseq Trisomy 18 Male- Matched Reference Material can be used to develop a new test, validate an assay, monitor routine performance, troubleshoot problems across the entire workflow and ensure overall proficiency with the same sustainable product.\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eMatched (or related) maternal-fetal Trisomy 18 (or Edwards Syndrome) male sample compatible with a broad range of NIPT assay methods\u003c\/li\u003e\n\u003cli\u003eProprietary method maintains native cfDNA size profile of ~170 bp size distribution and natural maternal-fetal size difference\u003c\/li\u003e\n\u003cli\u003eOffered in a plasma format capable of assessing the entire workflow from extraction through analysis (identical to clinical samples\u003c\/li\u003e\n\u003cli\u003eFetal fraction levels confirmed to be moderate-high positive to help establish initial baseline (can be customized to lower levels)\u003c\/li\u003e\n\u003cli\u003eManufactured in GMP-compliant and ISO 13485-certified facilities\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eDocuments\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/ps-mkt-00506-seraseq-nipt-rm-brochure.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq NIPT Reference Materials (Product Sheet)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/pi-0720-0171-seraseq-trisomy-18-male---matched-ref-mat.pdf\" target=\"_blank\" rel=\"noopener\"\u003ePackage Insert for Seraseq Trisomy 18 Male Matched Reference Material (Package Insert)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/pi-0720-0172-seraseq-trisomy-18-female-matched-rm.pdf\" target=\"_blank\" rel=\"noopener\"\u003ePackage Insert for Seraseq Trisomy 18 Female-Matched Reference Material (Package Insert)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/nrl-0710-0167.0171.0172.0779.0780-seraseq-matched-reference-material.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq Matched Reference Material Non-Requirement Letter (SDS Non-Requirement Letter)\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eOrdering Information\u003c\/h2\u003e\u003ctable\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eCat. no.\u003c\/th\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eSize\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e0720-0171\u003c\/td\u003e\n\u003ctd\u003eSeraseq® Trisomy 18 Male-Matched Reference Material\u003c\/td\u003e\n\u003ctd\u003e1 x 1 mL\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e0720-0172\u003c\/td\u003e\n\u003ctd\u003eSeraseq® Trisomy 18 Female-Matched Reference Material\u003c\/td\u003e\n\u003ctd\u003e1 x 1 mL\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"SeraCare","offers":[{"title":"Male","offer_id":46798514454607,"sku":"0720-0171","price":0.0,"currency_code":"ILS","in_stock":true},{"title":"Female","offer_id":46798514487375,"sku":"0720-0172","price":0.0,"currency_code":"ILS","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0712\/0748\/5519\/files\/0720-0171.jpg?v=1789655960"},{"product_id":"seracare-seraseq-22q11-matched-reference-material-0720-0173","title":"Seraseq® 22q11 Matched Reference Material","description":"\u003cp\u003eNon-invasive prenatal testing (NIPT) continues to expand globally and given the clinical implications, it is extremely critical that NIPT assays report back presence or absence of aneuploidies in an accurate and consistent manner. Matched maternal-fetal reference materials derived from pregnant maternal plasma enable accurate assessment of a broad range of NIPT assays, including those based on counting methods, SNPs, as well as differences in the length of maternal and fetal cfDNA.\u003c\/p\u003e \u003cp\u003eThe Seraseq 22q11 Male-Matched Reference Material can be used to develop a new test, validate an assay, monitor routine performance, troubleshoot problems across the entire workflow and ensure overall proficiency with the same sustainable product.\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eMatched (or related) maternal-fetal 22q11 (or DiGeorge Syndrome) male sample compatible with a broad range of NIPT assay methods\u003c\/li\u003e\n\u003cli\u003eMicrodeletion is at least 2Mb and includes TUPLE1 deletion\u003c\/li\u003e\n\u003cli\u003eProprietary method maintains native cfDNA size profile of ~170 bp size distribution and natural maternal-fetal size difference\u003c\/li\u003e\n\u003cli\u003eOffered in a plasma format capable of assessing the entire workflow from extraction through analysis (similar to clinical samples)\u003c\/li\u003e\n\u003cli\u003eFetal fraction levels confirmed to be a high positive to help establish initial baseline (can be customized to lower levels)\u003c\/li\u003e\n\u003cli\u003eManufactured in GMP-compliant and ISO 13485-certified facilities\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eDocuments\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/ps-mkt-00506-seraseq-nipt-rm-brochure.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq NIPT Reference Materials (Product Sheet)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/pi-0720-0173-seraseq-22q11-male-matched-rm.pdf\" target=\"_blank\" rel=\"noopener\"\u003ePackage Insert for Seraseq 22q11 Male-Matched Reference Material (Package Insert)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/pi-0720-0174-seraseq-22q11-female-matched-rm.pdf\" target=\"_blank\" rel=\"noopener\"\u003ePackage Insert for Seraseq 22q11 Female-Matched Reference Material (Package Insert)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/nrl-0710-0167.0171.0172.0779.0780-seraseq-matched-reference-material.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq Matched Reference Material Non-Requirement Letter (SDS Non-Requirement Letter)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/nrl-0710-0169-0174-seraseq-euploid.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq Euploid Reference Material Non-Requirement Letter (SDS Non-Requirement Letter)\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eOrdering Information\u003c\/h2\u003e\u003ctable\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eCat. no.\u003c\/th\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eSize\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e0720-0173\u003c\/td\u003e\n\u003ctd\u003eSeraseq® 22q11 Male-Matched Reference Material\u003c\/td\u003e\n\u003ctd\u003e1 x 1 mL\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e0720-0174\u003c\/td\u003e\n\u003ctd\u003eSeraseq® 22q11 Female-Matched Reference Material\u003c\/td\u003e\n\u003ctd\u003e1 x 1 mL\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"SeraCare","offers":[{"title":"Male","offer_id":46798514389071,"sku":"0720-0173","price":0.0,"currency_code":"ILS","in_stock":true},{"title":"Female","offer_id":46798514421839,"sku":"0720-0174","price":0.0,"currency_code":"ILS","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0712\/0748\/5519\/files\/0720-0173.jpg?v=1789655960"},{"product_id":"seracare-seraseq-trisomy-13-matched-reference-material-0720-0779","title":"Seraseq® Trisomy 13 Matched Reference Material","description":"\u003cp\u003eNon-invasive prenatal testing (NIPT) continues to expand globally, and given the clinical implicatons, it is extremely critical that NIPT assays report back presence or absence of aneuploidies in an accurate and consistent manner. Matched maternal-fetal reference materials derived from pregnant maternal plasma enable accurate assessment of a broad range of NIPT assays, including those based on counting methods, SNPs, as well as differences in the length of maternal and fetal cfDNA.\u003c\/p\u003e\u003cp\u003eThe Seraseq Trisomy 13 Male- Matched Reference Material can be used to develop a new test, validate an assay, monitor routine performance, troubleshoot problems across the entire workflow and ensure overall proficiency with the same sustainable product.\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eMatched (or related) maternal-fetal Trisomy 13 (or Patau Syndrome) male sample compatible with a broad range of NIPT assay methods.\u003c\/li\u003e\n\u003cli\u003eProprietary method maintains native cfDNA size profile of ~170 bp size distribution and natural maternal-fetal size difference.\u003c\/li\u003e\n\u003cli\u003eOffered in a plasma format capable of assessing the entire workflow from extraction through analysis (identical to clinical samples).\u003c\/li\u003e\n\u003cli\u003eFetal fraction levels confirmed to be moderate-high positive to help establish initial baseline (can be customized to lower levels).\u003c\/li\u003e\n\u003cli\u003eManufactured in GMP-compliant and ISO 13485-certified facilities.\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eDocuments\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/ps-mkt-00506-seraseq-nipt-rm-brochure.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq NIPT Reference Materials (Product Sheet)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/pi-0720-0779-seraseq-trisomy-13-male---matched-ref-mat.pdf\" target=\"_blank\" rel=\"noopener\"\u003ePackage Insert for Seraseq Trisomy 13 Male Matched Reference Material (Package Insert)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/pi-0720-0780-seraseq-trisomy-13-female.pdf\" target=\"_blank\" rel=\"noopener\"\u003ePackage Insert for Seraseq Trisomy 13 Female-Matched Reference Material (Package Insert)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/nrl-0710-0167.0171.0172.0779.0780-seraseq-matched-reference-material.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq Matched Reference Material Non-Requirement Letter (SDS Non-Requirement Letter)\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eOrdering Information\u003c\/h2\u003e\u003ctable\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eCat. no.\u003c\/th\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eSize\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e0720-0779\u003c\/td\u003e\n\u003ctd\u003eSeraseq® Trisomy 13 Male-Matched Reference Material\u003c\/td\u003e\n\u003ctd\u003e1 x 1 mL\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e0720-0780\u003c\/td\u003e\n\u003ctd\u003eSeraseq® Trisomy 13 Female-Matched Reference Material\u003c\/td\u003e\n\u003ctd\u003e1 x 1 mL\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"SeraCare","offers":[{"title":"Male","offer_id":46798514585679,"sku":"0720-0779","price":0.0,"currency_code":"ILS","in_stock":true},{"title":"Female","offer_id":46798514618447,"sku":"0720-0780","price":0.0,"currency_code":"ILS","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0712\/0748\/5519\/files\/0720-0779.jpg?v=1789655966"},{"product_id":"seracare-seraseq-turner-syndrome-xo-reference-material-0720-0952","title":"Seraseq® Turner Syndrome (XO) Reference Material","description":"\u003cp\u003eNon-invasive prenatal testing (NIPT) continues to expand globally, and given the clinical implications, it is extremely critical that NIPT assays report back presence or absence of aneuploidies in an accurate and consistent manner. Matched maternal-fetal reference materials derived from pregnant maternal plasma enable accurate assessment of a broad range of NIPT assays, including those based on counting methods, SNPs, as well as differences in the length of maternal and fetal cfDNA.\u003c\/p\u003e\u003cp\u003e\u003c\/p\u003e\u003cp\u003eThe Seraseq Turner Syndrome (XO) Reference Material can be used to develop a new test, validate an assay, monitor routine performance, troubleshoot problems across the entire workflow and ensure overall proficiency with the same sustainable product. Matched (or related) maternal-fetal XO sample compatible with a broad range of NIPT assay methods. Proprietary method maintains native cfDNA size profile of ~170 bp size distribution and natural maternal-fetal size difference. Offered in a plasma format capable of assessing the entire workflow from extraction through analysis (identical to clinical samples). Fetal fraction levels confirmed to be moderate-high positive to help establish initial baseline (can be customized to lower levels). Manufactured in GMP-compliant and ISO 13485-certified facilities.\u003c\/p\u003e\u003ch2\u003eDocuments\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/ps-mkt-00506-seraseq-nipt-rm-brochure.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq NIPT Reference Materials (Product Sheet)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/pi-0720-0952-seraseq-turner-syndrome-xo-ref-mtrl.pdf\" target=\"_blank\" rel=\"noopener\"\u003ePackage Insert for Seraseq Turner Syndrome (XO) Reference Material (Package Insert)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/pi-seraseq-turner-syndrome-xo-ref-mtrl-0720-0952.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq Turner Syndrome (XO) Reference Material (Package Insert)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/nrl-0710-0952-seraseq-turner-syndrome.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq Turner Syndrome Non-Requirement Letter (SDS Non-Requirement Letter)\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eOrdering Information\u003c\/h2\u003e\u003ctable\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eCat. no.\u003c\/th\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eSize\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\u003ctr\u003e\n\u003ctd\u003e0720-0952\u003c\/td\u003e\n\u003ctd\u003eSeraseq® Turner Syndrome (XO) Reference Material\u003c\/td\u003e\n\u003ctd\u003e1 x 1 mL\u003c\/td\u003e\n\u003c\/tr\u003e\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"SeraCare","offers":[{"title":"Default Title","offer_id":46798514782287,"sku":"0720-0952","price":0.0,"currency_code":"ILS","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0712\/0748\/5519\/files\/0720-0952.jpg?v=1789655967"},{"product_id":"seracare-seraseq-klinefelter-syndrome-xxy-reference-material-0720-0953","title":"Seraseq® Klinefelter Syndrome (XXY) Reference Material","description":"\u003cp\u003eNon-invasive prenatal testing (NIPT) continues to expand globally, and given the clinical implications, it is extremely critical that NIPT assays report back presence or absence of aneuploidies in an accurate and consistent manner. Matched maternal-fetal reference materials derived from pregnant maternal plasma enable accurate assessment of a broad range of NIPT assays, including those based on counting methods, SNPs, as well as differences in the length of maternal and fetal cfDNA.\u003c\/p\u003e\u003cp\u003e\u003c\/p\u003e\u003cp\u003eThe Klinefelter Syndrome (XXY) Reference Material can be used to develop a new test, validate an assay, monitor routine performance, troubleshoot problems across the entire workflow and ensure overall proficiency with the same sustainable product. Matched (or related) maternal-fetal XXY sample compatible with a broad range of NIPT assay methods. Proprietary method maintains native cfDNA size profile of ~170 bp size distribution and natural maternal-fetal size difference offered in a plasma format capable of assessing the entire workflow from extraction through analysis (identical to clinical samples). Fetal fraction levels confirmed to be moderate-high positive to help establish initial baseline (can be customized to lower levels). Manufactured in GMP-compliant and ISO 13485-certified facilities.\u003c\/p\u003e\u003ch2\u003eDocuments\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/pi-seraseq-klinefelter-syndrome-xxy-ref-mtrl-0720-0953.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq Klinefelter Syndrome (XXY) Reference Material (Package Insert)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/nrl-0710-0953-0954-seraseq-syndrome.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq Syndrome Non-Requirement Letter (SDS Non-Requirement Letter)\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eOrdering Information\u003c\/h2\u003e\u003ctable\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eCat. no.\u003c\/th\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eSize\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\u003ctr\u003e\n\u003ctd\u003e0720-0953\u003c\/td\u003e\n\u003ctd\u003eSeraseq® Klinefelter Syndrome (XXY) Reference Material\u003c\/td\u003e\n\u003ctd\u003e1 x 1 mL\u003c\/td\u003e\n\u003c\/tr\u003e\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"SeraCare","offers":[{"title":"Default Title","offer_id":46798514880591,"sku":"0720-0953","price":0.0,"currency_code":"ILS","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0712\/0748\/5519\/files\/0720-0953.jpg?v=1789655973"},{"product_id":"seracare-seraseq-jacobs-syndrome-xyy-reference-material-0720-0954","title":"Seraseq® Jacobs Syndrome (XYY) Reference Material","description":"\u003cp\u003eNon-invasive prenatal testing (NIPT) continues to expand globally, and given the clinical implications, it is extremely critical that NIPT assays report back presence or absence of aneuploidies in an accurate and consistent manner. Matched maternal-fetal reference materials derived from pregnant maternal plasma enable accurate assessment of a broad range of NIPT assays, including those based on counting methods, SNPs, as well as differences in the length of maternal and fetal cfDNA.\u003c\/p\u003e\u003cp\u003e\u003c\/p\u003e\u003cp\u003eThe Seraseq Jacobs Syndrome (XYY) Reference Material can be used to develop a new test, validate an assay, monitor routine performance, troubleshoot problems across the entire workflow and ensure overall proficiency with the same sustainable product. Matched (or related) maternal-fetal XYY sample compatible with a broad range of NIPT assay methods. Proprietary method maintains native cfDNA size profile of ~170 bp size distribution and natural maternal-fetal size difference offered in a plasma format capable of assessing the entire workflow from extraction through analysis (identical to clinical samples). Fetal fraction levels confirmed to be moderate-high positive to help establish initial baseline (can be customized to lower levels). Manufactured in GMP-compliant and ISO 13485-certified facilities.\u003c\/p\u003e\u003ch2\u003eDocuments\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/pi-seraseq-jacobs-syndrome-xyy-reference-material-0720-0954.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq Jacobs Syndrome (XYY) Reference Material (Package Insert)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/pi-0720-0954-seraseq-jacobs-syndrome-rm.pdf\" target=\"_blank\" rel=\"noopener\"\u003ePackage Insert for Seraseq Jacobs Syndrome (XYY) Reference Material (Package Insert)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/nrl-0710-0953-0954-seraseq-syndrome.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq Syndrome Non-Requirement Letter (SDS Non-Requirement Letter)\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eOrdering Information\u003c\/h2\u003e\u003ctable\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eCat. no.\u003c\/th\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eSize\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\u003ctr\u003e\n\u003ctd\u003e0720-0954\u003c\/td\u003e\n\u003ctd\u003eSeraseq® Jacobs Syndrome (XYY) Reference Material\u003c\/td\u003e\n\u003ctd\u003e1 x 1 mL\u003c\/td\u003e\n\u003c\/tr\u003e\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"SeraCare","offers":[{"title":"Default Title","offer_id":46798514946127,"sku":"0720-0954","price":0.0,"currency_code":"ILS","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0712\/0748\/5519\/files\/0720-0954.jpg?v=1789655976"},{"product_id":"seracare-seraseq-t21-male-matched-cfdna-0720-1100","title":"Seraseq® T21 Male Matched cfDNA","description":"\u003cp\u003eThe Seraseq Antepartum and Postpartum T21 (Trisomy 21) Male cfDNA are intended as reference materials for non-invasive prenatal testing (NIPT) of fetal Trisomy 21 in pregnant patients via cell-free DNA (cfDNA) analysis.\u003c\/p\u003e\n\u003cp\u003eThose products are derived from a naturally-occurring mixture of matched (or related) maternal and fetal circulating cell-free DNA in a pregnant donor’s blood sample whose male fetus has been diagnosed with a Trisomy 21 (Down’s Syndrome).\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eSeraseq Antepartum T21 Male cfDNA is derived from a pregnant patient’s blood sample carrying a male fetus with confirmed Trisomy 21.\u003c\/li\u003e\n\u003cli\u003eSeraseq Postpartum T21 Male cfDNA is derived from the same patient’s blood sample collected after birth.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eSupplied as purified cfDNA in 0.1X TE buffer, the Antepartum T21 Male cfDNA can be used as a Trisomy 21 reference material in assay development, validation, verification, analysis and routine monitoring of test performance as well as troubleshooting and training. It can be either used as supplied or diluted using the matching Seraseq Postpartum T21 Male cfDNA (cat# 0720-1101), in order to decrease the estimated fetal fraction of the sample and perform limit of detection (LoD) studies.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eDerived from a prenatal pregnant donor’s blood whose male fetus has been identified with a Trisomy 21 (or Down’s Syndrome)\u003c\/li\u003e\n\u003cli\u003eMatched (or related) maternal-fetal material compatible with a broad range of NIPT assay methods\u003c\/li\u003e\n\u003cli\u003eProprietary method preserves native cfDNA characteristics such as size profile of ~170 bp, SNP content and natural maternal-fetal size difference\u003c\/li\u003e\n\u003cli\u003eSupplied as purified cfDNA in 0.1X TE buffer which can be added during the library preparation step\u003c\/li\u003e\n\u003cli\u003eLong shelf-life and lot-to-lot consistency with high quality materials manufactured in GMP-compliant and ISO 13485-certified facilities under strict quality checks\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eDocuments\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/pi-0720-1100.1101-seraseq-antepartum-and-postpartum-t21-male-cfdna.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq Antepartum \u0026amp; Postpartum T21 Male cfDNA (Package Insert)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/nrl-seraseq-nipt-reference-materials.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq NIPT Reference Materials Non-Requirement Letter (SDS Non-Requirement Letter)\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eOrdering Information\u003c\/h2\u003e\u003ctable\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eCat. no.\u003c\/th\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eSize\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e0720-1100\u003c\/td\u003e\n\u003ctd\u003eSeraseq® Antepartum T21 Male cfDNA\u003c\/td\u003e\n\u003ctd\u003e1 x 25 µL\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e0720-1101\u003c\/td\u003e\n\u003ctd\u003eSeraseq® Postpartum T21 Male cfDNA\u003c\/td\u003e\n\u003ctd\u003e1 x 25 µL\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"SeraCare","offers":[{"title":"Antepartum","offer_id":46798515044431,"sku":"0720-1100","price":0.0,"currency_code":"ILS","in_stock":true},{"title":"Postpartum","offer_id":46798515077199,"sku":"0720-1101","price":0.0,"currency_code":"ILS","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0712\/0748\/5519\/files\/0720-1100.jpg?v=1789655983"},{"product_id":"seracare-seraseq-triple-x-syndrome-xxx-reference-material-0720-1069","title":"Seraseq® Triple X Syndrome (XXX) Reference Material","description":"\u003cp\u003eGiven the clinical implications, it is extremely critical that NIPT assays report back presence or absence of aneuploidies in an accurate and consistent manner. Matched maternal-fetal reference materials derived from pregnant maternal plasma enable accurate assessment of a broad range of NIPT assays, including those based on counting methods, SNPs, as well as differences in the length of maternal and fetal cfDNA.\u003c\/p\u003e\u003cp\u003eThe Seraseq Triple X SYndrome (XXX) Reference Material can be used to develop a new test, validate an assay, monitor routine performance, troubleshoot problems across the entire workflow, and ensure overall proficiency with the same sustainable product.\u003c\/p\u003e\u003cli\u003eMatched (or related) maternal-fetal Triple X Syndrome (or Trisomy XXX) sample compatible with a broad range of NIPT assay methods\u003c\/li\u003e\u003cli\u003eProprietary method maintains native cfDNA characteristics such as size profile of ~170 bp, size distribution, SNP content, and natural maternal-fetal size difference,\u003c\/li\u003e\u003cli\u003eOffered in a plasma format capable of assessing the entire workflow from extraction through analysis (identical to clinical samples)\u003c\/li\u003e\u003cli\u003eLong shelf-life and lot-to-lot consistency with high-quality materials manufactured in GMP-compliant and ISO 13485-certified facilities under strict quality checks,\u003c\/li\u003e\u003cli\u003eCustomization of fetal fraction, concentration, and material formulation (either in plasma or fragmented DNA in buffer format) available on request.\u003c\/li\u003e\u003ch2\u003eDocuments\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/pi-0720-1069-seraseq-triple-x-syndrome-xxx-rm.pdf\" target=\"_blank\" rel=\"noopener\"\u003ePackage Insert for Seraseq Triple X Syndrome (XXX) Reference Material (Package Insert)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/nrl-0710-1069-seraseq-triple-x.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq Triple X Syndrome (XXX) Reference Material Non-Requirement Letter (SDS Non-Requirement Letter)\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eOrdering Information\u003c\/h2\u003e\u003ctable\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eCat. no.\u003c\/th\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eSize\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\u003ctr\u003e\n\u003ctd\u003e0720-1069\u003c\/td\u003e\n\u003ctd\u003eSeraseq® Triple X Syndrome (XXX) Reference Material\u003c\/td\u003e\n\u003ctd\u003e1 x 1 mL\u003c\/td\u003e\n\u003c\/tr\u003e\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"SeraCare","offers":[{"title":"Default Title","offer_id":46798515109967,"sku":"0720-1069","price":0.0,"currency_code":"ILS","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0712\/0748\/5519\/files\/0720-1069.jpg?v=1789655983"}],"url":"https:\/\/www.danyel.co.il\/collections\/seracare.oembed","provider":"danyel biotech","version":"1.0","type":"link"}